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2Abstract  
Huntington's disease (HD) is a dominantly inherited neurodegenerative disease caused by an 
expanded CAG repeat in HTT. Many clinical characteristics of HD such as age at motor onset are 
determined largely by the size of HTT CAG repeat. However, emerging evidence strongly supports 
a role for other genetic factors in modifying the disease pathogenesis driven by mutant huntingtin. 
A recent genome-wide association analysis to discover genetic modifiers of HD onset age provided 
initial evidence for modifier loci on chromosomes 8 and 15 and suggestive evidence for a locus on 
chromosome 3. Here, genotyping of candidate SNPs in a cohort of 3,314 additional HD subjects 
yields independent confirmation of the former two loci and moves the third to genome-wide 
significance at MLH1, a locus whose mouse orthologue modifies CAG length-dependent 
phenotypes in a Htt-knock-in mouse model of HD. Both quantitative and dichotomous association 
analyses implicate a functional variant on ~32% of chromosomes with beneficial modifier effect 
that delays HD motor onset by 0.7 years/allele. Genomic DNA capture and sequencing of the 
modifier haplotype localize the functional variation to a 78 kb region spanning the 3’end of MLH1
and the 5’end of the neighboring LRRFIP2, and marked by an isoleucine-valine missense variant 
in MLH1. Analysis of eQTLs provides modest support for altered regulation of MLH1 and 
LRRFIP2, raising the possibility that the modifier affects regulation of both genes. Finally, 
polygenic modification score and heritability analyses suggest the existence of additional genetic 
modifiers, supporting expanded, comprehensive genetic analysis of larger HD datasets. 
3Introduction 
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder in which an
unstable expanded CAG trinucleotide repeat of > 35 units in HTT, the 4p16.3 gene encoding 
huntingtin (1), precipitates a characteristic movement disorder and premature death (2, 3). The 
length of the CAG expansion is the primary determinant of the rate of the HD disease process since 
its size is inversely correlated with the age at onset of neurologic symptoms (4-8). However, other 
genetic factors also play a role in influencing the time to onset (9, 10). A recent genome-wide 
association (GWA) analysis of the difference between actual and CAG-predicted age at onset in 
~4,000 HD individuals identified genome-wide significant modifier loci, one with two 
independent modifier signals on chromosome 15 and a single modifier signal on chromosome 8 
(11). In addition, a suggestive association signal was detected in chromosome 3p22.2 near mutL
homolog 1 (MLH1) (11), known for its involvement in DNA mismatch repair (12). Dominant loss 
of function mutation of MLH1 are associated with Lynch Syndrome (Hereditary Non-Polyposis 
Colon Cancer type 2 or HNPCC2; MIM#609310), in which tumors display instability of 
dinucleotide repeats.  The 3p22 GWA signal in our study contributed to pathway analyses that 
further highlighted a role for DNA maintenance processes in HD modification, supporting the 
hypothesis that somatic CAG instability may influence onset age suggested previously by a 
correlation between high instability of the expanded repeat in HD postmortem brain tissue and an 
earlier age at motor onset (13). Moreover, genetic ablation of the murine MLH1 homolog, Mlh1,
in Htt CAG repeat knock-in mice eliminated instability of the expanded repeat and ameliorated 
nuclear huntingtin staining, a striatal disease phenotype (14). To obtain independent confirmation 
of the loci on chromosomes 8 and 15 and to test the significance of several other potential modifier 
loci, especially that in 3p22.2, we employed the Fluidigm platform to genotype individual 
4candidate SNPs in a large independent cohort of HD individuals: 3,314 participants from the 
European Huntington's Disease Network (EHDN) Registry collection.  
Results 
Single SNP association analysis reveals a 3rd genome-wide significant modifier locus 
Study subjects analyzed here displayed distributions of age at onset corrected for CAG repeat size 
(i.e., residual age at onset) and minor allele frequencies (MAF) comparable to the previous GWA 
samples (Figures S1-S2).  A number of the top scoring SNPs from the original GWA study (11, 
15) were not suitable for the Fluidigm genotyping platform (https://www.fluidigm.com/), so we 
substituted other variants that captured the same modifier signals. Ultimately, we genotyped the 
replication set for rs34852161 at the chromosome 8 locus, rs150393409 and rs35811129 
representing independent modifier effects in the same region of chromosome 15, rs116483964 and 
rs1799977 at the 3p22.2 locus and individual SNPs at 57 additional loci chosen for being amenable 
to the platform and having a p-value < 0.005 in either quantitative or dichotomous analysis from 
the original GWA (11) (Table S1). Quantitative association analysis using residual age at motor 
onset as the phenotype revealed nominally significant scores for rs34852161 on chromosome 8 
and rs150393409 on chromosome 15, while rs35811129 on chromosome 15 yielded genome-wide 
significance (p-value 2E-10) in the replication set (Table 1; Table S2). In meta-analysis with the 
prior GWA study, all three yielded genome-wide significant scores, confirming the modifier 
effects reported previously (11).  At the 3p22.2 locus, both rs1799977 in MLH1 and rs116483964 
in the adjacent LRRFIP2 exhibited nominally significant p-values (Table 1). Meta-analysis 
5combining the replication data and GWA analysis results raised both to genome-wide significance 
(8.84E-09 and 1.19E-08, respectively) (Table 1; Figure 1A, filled red circles).   
As this finding adds an additional locus to the list of genome-wide significant HD modifiers, we 
also carried out dichotomous analysis to evaluate the possibility that the significant association in 
quantitative analysis was driven by a few individuals with extreme residuals. Comparison of allele 
frequencies between the top and bottom 20% phenotypic extreme samples from the combined data 
(1,478 samples for each extreme group) also revealed genome-wide significance for rs1799977 
(p-value, 5.3E-09) and rs116483964 (p-value, 5.6E-09) (Table 2A). Conditional analysis 
demonstrated that both SNPs appear to capture a single modifier effect (Table 2B). The minor 
allele of each SNP was associated with delaying age at onset by approximately 0.7 years, 
explaining 0.5% of the residual age at onset in the combined data set.  Of the remaining 57 
independent loci tested, none attained genome-wide significance in the meta-analysis of GWA and 
Fluidigm data sets, although 3 were nominally significant (p-value < 0.05) in the latter (Table S2).  
Narrowed localization of the Chr3 functional variation responsible for modification of HD
The rs1799977 minor allele is a missense (isoleucine to valine) variant in MLH1, with a reported 
allele frequency of about 32.5% in 1,000 Genomes Project Europeans. As noted above, MLH1 is 
involved in DNA mismatch repair (12, 16) and HD CAG repeat instability (14), and inactivating 
mutations are present in some Lynch Syndrome families (17). SNP rs116483964, with a 
comparable minor allele frequency, is in an early intron of the immediately adjacent gene, 
LRRFIP2, whose product, Leucine Rich Repeat (In FLII) Interacting Protein 2, is involved in 
protein-protein interactions that regulate Wnt-signaling (18). LRRFIP2 is deleted together with 
6MLH1 as a founder mutation in some Portuguese Lynch syndrome families (19). In the original 
GWA study, there were other SNPs with comparable p-values at this locus that were not amenable 
to genotyping on the Fluidigm platform. To seek the variation responsible for the modifier effect, 
we selected 7 unrelated HD subjects homozygous for the minor allele of rs144287831, the top SNP 
from the GWA analysis (11), and with positive age of onset residuals > 4, and performed genomic 
DNA capture and sequencing of the 771 kb region (Figure 1A, a blue horizontal bar; 
Chr3:36,832,273-37,603,667) spanning TRANK1, EPM2AIP1, MLH1, LRRFIP2, GOLGA4, 
C3orf35 and a portion of ITGA9. These 14 chromosomes from 7 HD individuals were near 
identical for all frequent (> 1%) reported SNPs across a haplotype of approximately 100 kb 
between Chr3:37,043,009-37,142,847 (Figure 1A, a red horizontal bar; Table S3). Encompassed 
by this haplotype were the minor alleles for the 7 top scoring markers from the GWA, all of which 
have a frequency of 0.31 - 0.32 in our HD dataset (Table 3). Each of these markers shows a striking 
shift of the minor allele toward the 4th quartile of the age of onset residual distribution, indicative 
of a contribution of a chromosome bearing this 7-marker haplotype to later than expected onset 
(Table 3).  
The GWA and capture sequencing data both argue that 0.31 - 0.32 is the frequency of the 
responsible functional modifier variation at this locus in European HD subjects. First, the 100 kb 
shared haplotype also contains many polymorphic sites of higher MAF (107 sites MAF > 0.32) in 
Europeans, but these all yielded weaker significance scores in both quantitative and dichotomous 
association analysis (Figure 1B, filled grey circles), indicating that signal from the allele on the 
modifier haplotype is diluted by the presence of the same allele on many non-modifier 
chromosomes. Second, all markers with MAF < 0.31 (70 sites with MAF > 0.02) yielded weaker 
7significance scores in the GWA analysis (Figure 1B, open grey circles), indicating that they did 
not fully capture the modifier effect and arguing against the effect being contributed by only a 
subset of the chromosomes marked by the top SNPs. Finally, our capture sequencing of these 14 
candidate modifier chromosomes did not identify any shared novel variants that could be 
responsible for modification (Table S3). Consequently, the modifier effect is likely to be due to 
one or more of the markers listed in Table 3, acting either individually or together through part or 
all of the haplotype that they define. Although we cannot completely exclude an undetected 
structural variation or a change in a simple sequence repeat, as these may remain cryptic to the 
capture sequencing used, we did exclude the presence of structural variations greater than a few 
kb using whole genome sequencing of large-insert jumping libraries (20, 21).  The most attractive 
candidate variant is rs1799977 since it alters the primary sequence of the MLH1 protein, may 
impact mildly on its interaction with PMS2 (22) and has been associated with allelic expression of 
the MLH1 transcript (23).  The ancestral A allele of rs1799977 specifies an isoleucine residue at 
position 219 that is conserved across mammals. The alternate G allele specifies valine, which is 
present in this conserved region of the MLH1 proteins of some reptiles, birds, fish and lower 
organisms, consistent with a functional but subtly different MLH1 protein.   In candidate studies, 
this I219V polymorphism has been tested as a low penetrance risk factor or modifier of various 
cancers, with mixed results, again suggestive of only a subtle functional impact (24-32).  Neither 
rs1799977 nor the other SNPs in the modifier haplotype are listed in the GWAS catalog (2017-02-
13 release) as associated with genome-wide significance to cancer or other human phenotypes.   
8Potential effect of the modifier haplotype on gene expression 
The two Chr3 markers used here both yielded significant eQTL signals with expression of multiple 
genes in the region (MLH1, LRRFIP2, and GOLGA4) in various tissues (GTEx portal, V6; 
http://www.gtexportal.org/home/). To examine whether the modifier haplotype contributes to any 
cis-eQTLs, we related the association signals for all GWA SNPs in the Chr3:36,800,000-
37,800,000 region (Figure 1) to eQTL signals for the local genes. We employed the HaploReg 
annotation tool (http://archive.broadinstitute.org/mammals/haploreg/haploreg.php) to determine 
the number of tissues in which the test SNP was significantly associated with expression of the 
test gene. The results revealed only modest correspondence between GWA modifier association 
signals and HaploReg eQTL data for MLH1 and a mildly stronger correspondence for LRRFIP2,
but no correspondence for other genes in the region (Figure S3). When we directly compared the 
strength of the GWA modifier association signal for each SNP with that of its eQTL signal in the 
GTEx database (Figure S4), we found a significant correlation between eQTL signals for LRRFIP2
in putamen and modifier association signals (Figure S4B, top right panel; Pearson's correlation, p-
value < 2.2E-16).  In an independent data set (BRAINEAC; http://www.braineac.org/), we did not 
see a significant eQTL association for MLH1 or LRRFIP2, but did observe correlated relationships 
between exon level QTL signals and modification signals for certain regions of LRRFIP2 (Figure 
S5). The modifier haplotype was associated with increased levels of LRRFIP2 but not MLH1
mRNA in brain tissues, but this gene-level analysis does not account for different transcript 
isoforms or address all brain regions (Figure S6; rs1799977). It remains uncertain which particular 
cell type is responsible for the modifier effect and whether there is a coincident impact on 
expression of any MLH1 transcript isoform. Notably, one rare transcript isoform of MLH1 is 
reported to overlap with LRRFIP2, suggesting the possibility that regulatory changes could in 
9some instances affect expression of both genes. More detailed molecular studies in human HD 
tissues will be required to determine the precise impact(s) of this modifier haplotype on both MLH1
and LRRFIP2. 
Genetic component of residual age at onset 
The four independent genome-wide significant modifier signals at 3 loci explain only a small 
portion of the variance in residual HD age at onset. Therefore, we evaluated the explanatory power 
of a polygenic modification score to determine the degree to which residual age at onset is better 
accounted for by a composite genetic score that includes many nominally associated SNPs. 
Overall, the effect sizes of 61 independent SNPs (only rs1799977 was used to represent 3p22.2) 
in the GWA data and in the replication samples were not significantly different (sign test p-value, 
0.609). Based upon effect sizes of SNPs estimated from the GWA analysis as a training set, a 
polygenic modification score was calculated for each of the 3,314 individuals in the Fluidigm data 
set. Then, residual age at onset was modeled as a function of polygenic modification score from 
the Fluidigm data. All 61 independent SNPs (one SNP for chromosome 3 and 60 other independent 
SNPs) were significant in the original GWA data (nominal p-value < 0.05) (Table S2), and the 
subsequently derived polygenic modification score explained a nominally significant amount of 
the variance in residual age at onset of the Fluidigm samples (p-value, 0.0157). Although 
somewhat biased, the polygenic modification score based on the Fluidigm samples (using SNPs 
with nominal p-value < 0.05) was highly significant in accounting for residual age at onset in HD 
subjects in the GWA data (p-value, 4.0E-26). When those missing genotypes in the Fluidigm test 
data set were assigned an expected genotype based upon allele frequency, the modification score 
became slightly more significant (Table S4), suggesting that missing genotypes and the smaller 
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size of test sample might have contributed to sub-optimal performance of the polygenic 
modification score in the Fluidigm data test set. Therefore, in order to judge the explanatory power 
of the polygenic modification score, we combined the GWA and Fluidigm data, and evenly split 
the data at random 1,000 times to generate training sets and corresponding test sets. Polygenic 
modification scores were then based on SNPs that passed pre-specified p-value thresholds in the 
training data: 0.05, 0.01, 0.001, 0.0001, and 0.00001. As summarized in Figure 2, the polygenic 
modification score became more significant and predictive as more SNPs were used to calculate 
individual polygenic modification score in the test samples. The top SNP alone explained 
approximately 1.3% of variance in residual age at onset (Figure 2). However, the polygenic 
modification score, representing the genetic predisposition to deviate from the expected age at 
onset for a given CAG repeat size, was yet more predictive. Polygenic modification scores based 
on SNPs with p-values smaller than 0.05, 0.01, 0.001, 0.0001, and 0.00001 in the training samples 
(Figure S7), explained approximately 5.3, 3.9, 2.8, 2.4, and 2.3% of the variance in residual age at 
onset of the test samples, respectively. The substantially increased R-squared values by polygenic 
modification score support the notion that HD onset can be modified by many genes with small 
effect sizes, even though the SNPs tagging those genes are not by themselves genome-wide 
significant in the current data sets. To evaluate the total amount of variance in residual age at onset 
explained by all SNPs collectively, we performed GCTA analysis using all QC-passed SNPs in 
the GWA data. The SNPs collectively explained approximately 20% of the variance in residual 
age at onset. Notably, 18% of the variance is due to SNPs other than those in the top chromosome 
15 region, as revealed by exclusion of the chromosome 15 modifier signals from the analysis. The 
reported GWA analysis therefore did not have sufficient power to discover all of the genetic 
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variation that modifies HD onset, arguing for continuation of this strategy with the largest 
achievable sample size.  
Discussion 
In summary, with candidate genotyping of HD individuals we have confirmed HD modifier loci 
on chromosomes 8 and 15 and identified the MLH1 region of chromosome 3 as an additional 
genome-wide significant modifier locus, while polygenic modification score analyses suggest that 
increasing the sample size of the GWA could identify yet more loci. The chromosome 3  modifier 
locus highlights MLH1, involved in brain tissue CAG instability in Htt knock-in mice (14), 
consistent with the hypothesis that a functional impact of genetic variation in the modifier 
haplotype, via effects on CAG instability in the brains of HD patients, may alter CAG repeat size 
and thereby affect the rate of the disease process (13). This hypothesis is supported by the results 
of our GWA pathways analysis, which highlighted biological processes related to DNA 
maintenance (11). The functional variation within the modifier haplotype is associated with a delay 
in age at onset of 0.7 years, possibly consistent with an MLH1 hypomorphic variant that reduces 
somatic expansion of the CAG repeat due to reduced MLH1 activity. In any event, the impact of 
the functional variation on MLH1 is likely to be subtle, as complete loss of function of the allele 
would be expected to predispose to Lynch Syndrome. The correspondence between GWA 
significance and eQTL results for SNPs across the region also raises the possibility that a potential 
regulatory effect on LRRFIP2 also contributes, either directly or indirectly via a coincident effect 
on MLH1, to the observed delay in onset. Clearly additional genetic and molecular analyses will 
be required to test the effects of the modifier haplotype and the mechanism by which it delays the 
rate of HD pathogenesis. Finally, our finding that a substantial amount of variation in HD age at 
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onset can be accounted for by genetic modification suggests that expanded GWA analysis with 
more subjects and therefore greater power could reveal additional modifier loci and biological 
networks of genes that offer bona fide therapeutic targets, validated in humans that influence the 
HD disease process.  
Materials and Methods 
Genotyping and quality control analysis 
Selection of SNPs based on the recently completed GWA analysis (11) involved choosing the most 
significant SNPs amenable to genotyping on the Fluidigm platform for each of the top 61 
independent modifier signals. Genotyping of 67 SNPs, representing 61 independent signals, was 
performed by the Genomics Platform at the Broad Institute on an independent HD cohort of 3,314 
HD subjects from the European Huntington’s Disease Network Registry Study.  All SNPs had 
genotyping call rate greater than 90% and Hardy-Weinberg equilibrium p-value greater than 0.01. 
Non-independent SNPs with lower call rates were excluded from the polygenic modification score 
analysis. The study was approved by the Institutional Review Board of Partners HealthCare and 
all subjects provided informed consent for participation in HD research. 
Residual age at motor diagnosis as a phenotype for association analysis 
Age at onset of motor signs was based on rater estimation where available (1,443 subjects). In the 
absence of a rater estimate, we used age at onset data provided by family members (63 subjects) 
or patients (1,808 subjects). Predicted onset age was based on a phenotypic regression model 
describing the relationship between CAG repeat on the expanded chromosome and recorded age 
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at onset (6). Predicted age at onset was subtracted from observed age at onset to calculate the 
residual age at onset of motor signs, whose deviation from expectation represents the individual 
HD patient's level of modification of age at onset. For stringent replication analysis, we analyzed 
HD subjects with 40-55 CAG repeats with residual age at onset values within the range of the 
initial GWA data; since the most extreme data points have a greater potential for representing data 
entry or transcription errors, we excluded 5 subjects with extreme onset residuals beyond the range 
seen in the original GWA (Figure S1). 
Association analysis, meta-analysis, conditional analysis, and extreme dichotomous analysis 
In the Fluidigm data set, residual age at onset was modeled as function of a test SNP (additive 
model) and sex using a linear regression model. Main effect for sex was not significant in any 
association models. The small number of SNPs chosen for Fluidigm typing for the replication 
study were not sufficiently informative to distinguish sub-populations (data not shown). However, 
we reasoned that the discovery data set and replication data set have similar characteristics in terms 
of ancestry because of most individuals were from European countries. In addition, comparison of 
allele frequencies of replication SNPs in discovery and replication data sets revealed highly strong 
positive correlation (Figure S2), suggesting overall ancestry similarities between the two data sets.  
Subsequently, meta-analysis was performed by combining previous GWA results (11) and the 
current association results using the METAL program 
(http://genome.sph.umich.edu/wiki/METAL_Documentation) (33). Genome-wide significance 
was judged by meta-analysis p-value of 5E-8. To evaluate independence of chromosome 3 SNPs, 
GWA data and Fluidigm data were combined to perform conditional analyses. Briefly, residual 
age at onset was modeled as a function of either 1) rs1799977, 2) rs116483964, and 3) rs1799977 
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and rs116483964 together. Fixed effect linear regression models with sex covariate were 
constructed for conditional analysis. In addition, for chromosome 3 SNPs, we combined GWA 
data and Fluidigm data to perform combined extreme dichotomous analysis in which data were 
sorted based on the residual age at onset phenotype, and samples with the top and bottom 20% 
residual age at onset values were extracted (1,478 samples in each group). Logistic regression 
analysis was performed using extreme dichotomous phenotype as the dependent variable, a SNP 
as a primary continuous independent variable and sex as a covariate.  
Capture sequencing analysis 
Based on GWA analysis results, we chose 7 individuals who carry two minor alleles for the Chr3 
top GWA SNP (i.e., rs144287831) with residual age at onset greater than 4 years. Since conditional 
analysis suggested the top SNP tags a single modifier chromosome, chosen HD subjects were 
hypothesized to carry two copies of the modifier haplotype. Design of capture probes was based 
on the Agilent’s SureDesign online tool (https://earray.chem.agilent.com/suredesign/). A genomic 
region chr3:36,832,273-37,603,667 (hg19) was chosen in the SureDesign website in order to 
obtain ultra-long 120-mer biotinylated RNA bait probes that cover each site in the target region 5 
times.  To capture the entire genomic region including repeat sequences, we implemented an 
iterative capture probe design method. First, we input the chr3:36,832,273-37,603,667 as one 
contiguous region in the SureDesign website for most stringent probe design, generating 27,364 
capture probes covering 63.9% of the target region. The most stringent condition will exclude 
repeat sequences based on repeat annotations such as RepeatMasker 
(http://www.repeatmasker.org/), WindowMasker (34), and Duke Uniqueness 35 
(http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg18&g=wgEncodeMapability).  Secondly, un-
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captured regions (663 fragmented regions) from the previous design were fed into the program 
again for moderate stringent design, generating 8,794 capture probes covering 48.13% of the target 
region. Thirdly, remaining uncaptured regions (7,272 regions) were fed into the program for least 
stringent probe design, generating 14,544 probes (covering 89.79% of the target region). Lastly, 
remaining regions were used for probe design without any stringency (3,276 probes covering 
100% of target region). Thus, repeat sequences are likely to be captured by probes designed based 
on no stringency.  In order to focus on unique sequence but still capture the entire region, we 
replicated probe sets designed by most, moderate, and least stringent parameters.  Target DNA 
capture/enrichment was based on the SureSelect method (SureSelect XT2 Target Enrichment 
System) (35).  Briefly, each genomic DNA sample was sheared to produce smaller fragments, and 
indexed for multiplexing. Subsequently, pooled indexed DNA was hybridized with capture probes, 
and DNA-probe complexes were pulled down using magnetic streptavidin beads.  Enriched 
multiplexed libraries were sequenced for 100 bp paired-end sequencing using Illumina HiSeq at 
the Broad Institute. Mean per base coverage was 174.7; 94.0% and 97.4% of the region has at least 
10X and 5X coverages, respectively.  Sequencing data were then analyzed using the Genome 
Analysis Toolkit (https://software.broadinstitute.org/gatk/). We followed the Best Practices 
workflow to perform quality control analysis, variant discovery, and genotype calling (36).   
Comparison of HD GWA modification signals to tissue eQTL signals 
To determine whether modification of HD captured by significant chromosome 3 SNPs might be 
mediated by differential expression levels of genes in the region, we compared GWA association 
signals to HaploReg, GTEx eQTL data, and BRAINEAC exon level eQTL data. Initially, we 
counted the number of tissues in which a test SNP and a test gene were significantly associated 
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using HaploReg web resources, which annotated GTEx and other eQTL data sets. Due to potential 
tissue-specific regulation of gene expression, directions of eQTLs were not considered. 
Subsequently, we evaluated the patterns of correlation between modifier GWA significances and 
the number of significant tissues for each corresponding SNP. Next, we analyzed GTEx data 
focusing on brain regions and two candidate genes, MLH1 and LRRFIP2. Cortex, caudate, 
putamen and cerebellum in GTEx data were analyzed to evaluate correspondence between tissue-
specific cis eQTL signals and HD modification signals. Focusing on MLH1 and LRRFIP2 in 
putamen, exon array expression data from BRAINEAC were analyzed to test eQTL association 
with SNPs in the region, and subsequently eQTL signals were compared to HD GWA modifier 
association signals. Mapping of SNPs in eQTL data and HD GWA data was based on genomic 
coordinates (hg19 assembly).  
Polygenic modification score analysis 
In order to determine the explanatory power of a polygenic modification score in explaining the 
individual deviation from the expected age at onset for a given CAG size, we 1) obtained effect 
sizes and significances of SNPs from the initial GWA analysis (11), 2) calculated a modification 
score for the individual test sample (Fluidigm data) by summing the products of test SNP allele 
counts and corresponding effect sizes (http://zzz.bwh.harvard.edu/plink/profile.shtml), and 3) 
performed linear regression analysis by modeling residual age at onset of the test samples as a 
function of the polygenic modification score. The same procedure was applied for polygenic 
modification score analysis using Fluidigm data as a training set and GWA data as a test set. Only 
independent SNPs were used in this analysis. When SNPs were not independent (based on 
conditional analysis in the initial GWA data), the SNP with the highest genotyping call rate in the 
17
Fluidigm data was chosen to represent the association signal in the region; 61 independent SNPs 
were used to drive polygenic modification scores of test samples. Chromosome 3p22.2 was 
represented by rs1799977. Among the 61 independent SNPs, all of which were associated (p-value 
< 0.05) with residual age at onset in the GWA data, 7 were associated (nominal p-value < 0.05) in 
the Fluidigm data.  Missing genotypes in the Fluidigm test samples were ignored. Additionally, 
we also performed polygenic modification score analysis based on imputed Fluidigm test data by 
assigning expected genotypes based on allele frequency in the Fluidigm data. For a given missing 
SNP site in an individual, expected genotype in the dosage format was calculated by multiplying 
allele frequency of that SNP in the replication data set by 2 as described in the PLINK  program 
manual (http://zzz.bwh.harvard.edu/plink/profile.shtml). The polygenic modification score was 
then calculated for each individual in the test samples to be used as a predictor variable of a linear 
regression model to explain residual age at onset of test samples. Polygenic modification score 
was defined as the mean of effect size of a minor allele X minor allele count based on non-missing 
SNPs.  
Polygenic modification score analysis based on randomly chosen training and test samples 
from the combined data  
Our Fluidigm validation data set had missing data. Missing data in the test samples may reduce 
the accuracy of polygenic modification score when ignored or expected genotypes were assigned. 
To objectively evaluate the power of polygenic modification score, we 1) combined the GWA data 
and Fluidigm data, 2) randomly and evenly split into training samples (3,698 samples) and test 
samples (3,698 samples), 3) performed association analysis using genotype and residual age at 
onset of training samples, 4) calculated polygenic modification score of test samples based on 
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effect size estimation from the training sample analysis and allele count of test samples, and 5) 
evaluated the significance of the polygenic modification score in explaining residual age at onset 
of test samples. This procedure was repeated 1,000 times to obtain unbiased estimations. Missing 
genotype data in the test samples were excluded from calculating the polygenic modification score. 
Scoring SNPs were based on association p-value of 0.05, 0.01, 0.001, 0.0001, and 0.00001 in the 
training samples. All SNPs were used as scoring SNPs as long as they passed the pre-specified 
significance thresholds.  
GCTA analysis  
The overall genetic contribution to residual age at onset was calculated by the GCTA (Genome-
wide Complex Trait Analysis) program. Briefly, GWA data were analyzed by the restricted 
maximum likelihood (REML) method using the following parameters: --grm-adj, 0 and --grm-
cutoff, 0.025. For standard GCTA analysis, all QC-passed SNPs in the GWA data were analyzed. 
The chromosome 15:31,105,000-31,315,000 region harbors two independent genome-wide 
significant modification signals (11). Therefore, this region was excluded from the GWA data to 
estimate the contribution of the chromosome 15 region to modification of age at onset.  
Genomic coordinates 
GRCh37/hg19 was used. 
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Figure Legends 
Figure 1. Summary of meta-analysis for the chromosome 3 locus. 
A. GWA analysis results are shown as open grey circles, except the top SNPs shown as black 
circles. For two of the latter, Fluidigm genotyping data was generated on an independent study 
sample and subsequent meta-analysis revealed genome-wide significance for both SNPs (filled red 
circles). Arrows show the levels of improvement by addition of Fluidigm data. X-axis and Y-axis 
denote genomic coordinates (hg19 assembly) and significance of association, respectively. A line 
in cyan represents the recombination rate based on HapMap data (secondary Y-axis). A red dashed 
horizontal line marks the level of genome-wide significance, and a blue horizontal line indicates 
the region that was analyzed by capture sequencing analysis. All exons of transcripts (RefSeq) 
representing the same gene were combined to represent each gene in this region. Genes in red and 
blue denote genes on plus and minus strand, respectively. A red horizontal bar indicates a region 
expanded in panel B. 
B. Expanded region denoted by the red horizontal bar in Panel A. Filled black circles, filled grey 
circles, and open grey circles represent SNPs with allele frequencies between 31 and 32%, higher 
than 32%, and below 31%, respectively. IDs of SNPs with minor allele frequency between 31 and 
32% are shown. This region harbors exons of various transcripts from the 3’ portion of MLH1
(red) and the 5’ portion of LRRFIP2 (blue). Representative transcripts with different exons in this 
region were obtained from RefSeq and UCSC Genome Browser. 
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Figure 2. Increased explanatory power of the polygenic modification score. 
Combined data were randomly split into a training and test set of equal size to perform polygenic 
modification score analysis. For a given split, polygenic modification score in the test samples was 
calculated based on independent SNPs with training set p-value smaller than 0.05 (purple), 0.01 
(red), 0.001 (green), 0.0001 (blue) or 0.00001 (orange). Then, linear regression analysis was 
performed by modeling residual age at onset of test samples as a function of polygenic 
modification scores based on multiple SNPs with different levels of training set association 
analysis p-value. For each iteration, we recorded p-value and R-square value of the polygenic 
modification score. The main plot in the center shows significance (Y-axis) and percent R-squared 
values of polygenic modification score. Histograms on the top and on the right side of the main 
plot show the distributions of R-squared and significance values, respectively. As a reference, 
significance and R-squared value of the model based on the single most significant SNP are shown 
in grey.   
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MAF Beta p-value MAF Beta p-value
rs34852161 8 103,284,508 C A 0.083 -1.48 3.43E-07 0.084 -0.87 0.00737 2.39E-08 UBR5
rs150393409 15 31,202,961 G A 0.016 -5.54 9.34E-18 0.013 -2.38 0.00307 5.95E-17 FAN1
rs35811129 15 31,241,346 G A 0.272 1.37 1.16E-13 0.265 1.29 2.0E-10 1.55E-22 MTMR10
rs1799977 3 37,053,568 A G 0.319 0.89 7.16E-07 0.305 0.59 0.00258 1.19E-08 MLH1




* Results of linear regression analysis of candidate SNPs using GWA data and replication data are summarized. For both SNPs, 4
alternative alleles (test alleles) are minor alleles in our data. Chr, MAF, and beta represent chromosome, minor allele frequency, and 5
slope estimation, respectively.  6
$ Genes represent nearest genes, not necessarily causal modifier genes.  7
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rs1799977 conditioned by rs116483964 0.9818
rs116483964 conditioned by rs1799977 0.5145
3
* For dichotomous analysis, extreme late and extreme early groups (1,478 samples for each 4
group) comprising top and bottom 20% of subject based on samples sorted by residual age at 5
onset in a descending order were identified from combined data set (GWA data + Fluidigm data). 6
Then, logistic regression analysis was performed for each SNP using the test SNP as the main 7
predictor variable and sex as a covariate. For conditional analysis, GWA data and Fluidigm data 8
were combined to perform fixed effect model linear regression analysis to determine 9
independence of the two SNPs. Two SNPs were used simultaneously as independent variables in 10
a linear regression model, and corresponding p-values are obtained. For extreme dichotomous 11
phenotype analysis, 2 subsets of data were extracted from the combined data set based on 12
residual age at onset phenotype. 13
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Table 3. Modifier haplotype defined by top-scoring SNPs* 1



























analysis of AO 
residual
P-value dichotomous 
analysis of AO residual 
20% extremes
rs1799977 37,053,568 G A 0.319 0.279 0.298 0.324 0.351 7.2E-07 2.7E-06
rs144287831 37,068,079 C T 0.312 0.279 0.297 0.322 0.350 2.2E-07 1.5E-06
rs141716664 37,078,200 T - 0.315 0.281 0.299 0.323 0.350 4.4E-07/ 3.5E-06
rs116483964 37,102,696 A G 0.320 0.279 0.296 0.322 0.351 4.0E-07 2.1E-06
rs148648107 37,118,345 A G 0.318 0.280 0.297 0.323 0.350 9.6E-07 4.3E-06
rs11714838 37,121,844 A G 0.318 0.281 0.297 0.323 0.352 1.3E-06 5.0E-06
rs147891316 37,131,815 T G 0.317 0.280 0.297 0.323 0.351 1.1E-06 7.8E-06
*Allele frequencies of SNPs in GWA data were analyzed to localize functional variation. Subjects in GWA analysis were grouped into 2
quartile bins based on their residual age at onset; 1st and 4th AO residual quartiles represent earliest and latest age at onset groups, 3
respectively. Then, minor allele frequencies of SNPs were calculated for each quartile bin to understand how alleles are distributed 4
relative to residual age at onset phenotype. MAF means minor allele frequency. P-value quantitative analysis of AO residual 5
represents the p-value in the original GWA analysis. P-value dichotomous analysis of AO residual 20% extremes represent p-values 6




EHDN: European Huntington’s Disease Network3
eQTL: expression Quantitative Trait Locus 4
GCTA: Genome-wide Complex Trait Analysis 5
GWA: Genome-wide Association 6
HD: Huntington’s Disease7
MAF: minor allele frequency 8
QC: quality control 9




Table S1 - Genotype of replication samples
See excel file TableS1.xls
Table S2. SNPs analyzed in replication samples and for polygenic modification score
See excel file TableS2.xls
2Table S3. Consensus alleles of the effect haplotype. *









rs4647224 3 37,043,230 G A A 14
rs59335282 3 37,043,443 GT G G 14
rs28393182 3 37,043,459 T G G 14
rs3774341 3 37,045,233 A C C 14
rs9871903 3 37,047,433 G A A 14
rs113479434 3 37,047,777 G A A 14
rs4234259 3 37,048,633 A G G 14
rs4647250 3 37,049,098 T C C 14
rs113956733 3 37,052,070 T C C 14
rs1799977 3 37,053,568 A G G 14
rs4647260 3 37,054,601 T C C 14
rs1558528 3 37,056,990 C A A 14
rs4647269 3 37,057,591 C T T 14
rs4647277 3 37,058,509 A G G 14
rs11710807 3 37,060,321 C T T 14
rs141017393 3 37,060,733 G A G 13
rs2286939 3 37,062,040 T C C 14
rs3774339 3 37,062,854 C T T 14
rs3774338 3 37,062,959 G T T 14
rs28754348 3 37,063,728 G A A 14
rs186532057 3 37,065,425 G A G 13
rs6550445 3 37,066,369 T C C 14
rs6550446 3 37,066,373 T A A 14
rs11129748 3 37,067,050 A G G 14
rs144287831 3 37,068,079 T C C 14
rs6781146 3 37,068,257 C T T 14
3rs143397020 3 37,068,331 GAATAATAAT G G 14
rs9852810 3 37,068,969 G A A 14
rs11719992 3 37,069,872 T G G 14
rs2286940 3 37,070,106 C T T 14
rs3774335 3 37,072,627 A C C 14
rs3774334 3 37,072,705 G A A 14
rs9819025 3 37,073,287 T G G 14
rs6765395 3 37,073,579 T G G 14
rs3821826 3 37,074,368 C G G 14
rs997588 3 37,075,142 G A A 13
rs6772548 3 37,075,934 T C C 14
rs6784088 3 37,075,984 A G G 14
rs6550447 3 37,078,280 G C C 14
rs4678925 3 37,078,506 A G G 14
rs748766 3 37,082,874 T C C 14
rs9876116 3 37,083,740 A G G 14
rs67401825 3 37,085,970 T C C 14
rs9822082 3 37,086,204 G A A 14
rs75839046 3 37,086,416 A G A 12
rs184308009 3 37,087,179 T C T 12
rs9831178 3 37,087,417 C T T 14
rs11926842 3 37,088,102 A T T 14
rs11290150 3 37,089,840 CT C C 14
rs2241031 3 37,090,274 C T T 14
rs1860968 3 37,091,325 G A A 14
rs1558529 3 37,093,064 T C C 14
rs4579 3 37,094,679 G A A 14
rs10849 3 37,095,070 C T T 14
rs4678932 3 37,096,303 T G G 14
rs2110194 3 37,097,087 C T T 14
4rs2363499 3 37,097,546 A G G 14
rs202119305 3 37,097,949 CT C C 14
rs143498278 3 37,098,064 C T C 10
rs58257408 3 37,099,025 CT C C 14
rs3774327 3 37,099,367 G A A 14
rs3774326 3 37,099,566 G A A 14
rs7639327 3 37,099,788 A G G 14
rs202036094 3 37,100,166 CAAA C C 14
rs7372653 3 37,101,079 G A A 14
rs11720064 3 37,101,519 G T T 14
rs139922612 3 37,102,458 AGTGC A A 14
rs58693636 3 37,102,623 C T T 14
rs116483964 3 37,102,696 G A A 14
rs145261675 3 37,102,874 CTTTTCT C C 14
rs6808735 3 37,104,246 A C C 14
rs2058476 3 37,104,896 G T T 14
rs1468712 3 37,106,013 T C C 14
rs1468713 3 37,106,115 A G G 14
rs7639375 3 37,107,022 C A A 14
rs2302503 3 37,107,470 G A A 14
rs6550448 3 37,108,896 T A A 14
rs56180213 3 37,109,633 C A A 14
rs9823428 3 37,111,130 G A A 14
rs17810211 3 37,113,405 T C C 14
rs3836485 3 37,115,313 GC G G 14
rs1558527 3 37,115,658 T C C 14
rs7651033 3 37,116,042 C T T 14
rs2302504 3 37,116,386 G T T 14
rs11709376 3 37,116,808 C G G 14
rs726769 3 37,117,741 A G G 14
5rs148648107 3 37,118,345 G A A 14
rs4678935 3 37,119,835 A C C 14
rs9810355 3 37,121,074 A G G 14
rs6806487 3 37,121,092 C T T 14
rs6806861 3 37,121,293 G A A 14
rs9814918 3 37,121,613 A G G 14
rs11707197 3 37,122,329 A C C 14
rs6550449 3 37,122,997 A G G 14
rs6550450 3 37,123,099 C G G 14
rs6550451 3 37,123,250 G A A 14
rs1990492 3 37,124,620 A G G 14
rs9846039 3 37,125,699 C T T 14
rs113687377 3 37,127,076 CT C C 14
rs3821824 3 37,130,942 G C C 14
rs2302505 3 37,131,404 C T T 14
rs147891316 3 37,131,815 G T T 14
rs9879135 3 37,132,279 G A A 14
rs113267946 3 37,132,719 GA G G 14
rs2302506 3 37,133,124 A G G 14
rs11915301 3 37,133,853 G A A 14
rs3774323 3 37,134,451 T C C 14
rs17204675 3 37,135,797 T C C 14
rs9820888 3 37,136,711 T G G 14
rs67385735 3 37,138,751 A G G 14
rs5847949 3 37,139,597 AT A A 14
rs7638252 3 37,141,732 G C C 14
rs57588408 3 37,141,928 CAT C C 14
rs7616160 3 37,141,977 A G G 14
rs143418804 3 37,142,394 T C T 13
rs571725354 3 37,064,415 G A G 13
6rs554553185 3 37,100,477 A G A 13
rs527583094 3 37,126,407 T C T 13
* Seven HD individuals who carry two minor alleles for rs144287831 were captured to determine 
the sequence of Chr3:36 ,832,347-37,603,667 region. Variable sites and alternative alleles in 7 
individuals were detected in the capture sequencing data, and consensus alleles among 14 
chromosomes in this region were identified by taking the most frequent alleles for each site. 
Therefore, consensus alleles in this table represent either 1) reference or alternative alleles 
predominant in 14 chromosomes, or 2) alternative alleles present on all 14 chromosomes. For 
each site, the number of defined consensus allele s was counted among 14 chromosomes. For 
example, 14 means all 14 chromosomes carry the consensus allele for a given site. 




Test set Score SNPs
Handling of missing 
genotype in the test set
P-value
A GWA Fluidigm










p-value < 0.05 in the 
training set
Expected genotype was 
assigned based on 
allele frequency
0.0144
* Using 61 independent SNPs typed in the Fluidigm data, we performed polygenic modification 
score analysis. 
A) GWA data were analyzed to estimate effect size of SNPs and to calculate p-values. 
Subsequently, the polygenic modification score of Fluidigm data based on SNPs with GWA 
analysis p-value smaller than 0.05 was calculated. Then, residual age at onset of Fluidigm 
samples was modeled as a function of polygenic modification score in a linear regression model 
to determine its explanatory power. 
B) The same procedures were performed using Fluidigm data as a training set and GWA data as a 
test set. 
C) The same SNPs as in analysis A were used to calculate the polygenic modification score of 
Fluidigm data imputed for missing genotype. For a missing site in a given individual, allele 
frequency of the minor allele multiplied by 2 was used as an expected genotype to calculate the 
polygenic modification score. The same analytical pipeline was used to determine the 
significance of the polygenic modification score. 
8Supplemental Figures
9Figure S1. Residual age at onset phenotype of replication data. 
Distribution of residual age at onset of replication samples (histogram in blue) was compared to 
that of GWA data (histogram in red) to visually confirm the homogeneity of phenotypes of 
replication samples and GWA samples. 
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Figure S2. Minor allele frequencies of test SNPs in the discovery and replication data sets 
For 61 SNPs we focused on for the replication analysis, minor allele frequencies in discovery set 
(GWA data; X-axis) and replication set (Fluidigm data; Y-axis) are compared.
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Figure S3. Correspondence between GWA modification signals and cis eQTL signals. 
To explore the molecular mechanisms of modification conferred by the chromosome 3 locus, we 
determined whether GWA modifier association signals were similar to eQTL signals in tissues. 
For a given gene, we counted the number of significant tissues associated with SNPs in the 
HaploReg annotation data base regardless of the effect sizes. Each gene was graphed using two 
plots. The plot on the left shows GWA association signal on the primary Y-axis (grey circles) and 
the number of tissues with significant eQTLs on the secondary Y-axis (black crosses) for all 
SNPs. For shared SNPs between our GWA data and HaploReg data base, significance (-log10p-
value) in GWA data (X-axis) were directly compared to the number of significant tissues (plot on 
the right). 
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Figure S 4. SNPs associated with expression levels of MLH1 and LRRFIP2 in brain sub-
regions.
MLH1 and LRRFIP2 showed promising correspondence with cis eQTL signals. Subsequently, 
we evaluated the brain eQTL signals in GTEx data, and compared to our GWA modifier signals. 
Caudate (top left), putamen (top right), cortex (bottom left), and cerebellum (bottom right) were 
analyzed for eQTL data in GTEx data (version 6). Significance of SNPs is represented by -
log10(p-value) on both axes. 
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Figure S 5.  Relationship between cis eQTL signals for LRRFIP2 in putamen and GWA 
modification association signals in BRAINEAC data.
BRAINEAC data (http://www.braineac.org/) was analyzed to further evaluate the impacts of 
SNPs on mRNA expression levels of MLH1 and LRRFIP2 in putamen. 129 putamen samples 
were analyzed in BRAINEAC. Expression levels of each region determined by BRAINEAC 
were modeled as a function of SNP in a linear regression analysis framework. Then, 
significances (i.e., -log10(p-value) from eQTL analysis (Y-axis) were compared to significances 
from HD onset modifier GWA analysis (X-axis; -log10(p-valud)). Most of exons of MLH1 or 
LRRFIP2 did not show trends of correlation between eQTL signals and GWA modifier 
association signals. However, eQTL signals for chr3:37 ,108,538-37,110,067 (A; 21st intron of 
LRRFIP2, NM_006309.3) and chr3:37 ,138,107-37,138,136 (B; 16th exon of LRRFIP2, 
NM_006309.3) in putamen weakly corresponded with modifier association signals. 
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Figure S6. Association of rs116483964 and rs1799977 with the expression levels of MLH1
and LRRFIP2 in brain regions. Expression levels of MLH1 (open symbols) and LRRFIP2
(filled symbols) in putamen (circle), caudate (square), cortex (diamond), and cerebellum 
(triangle) were compared against rs1799977 in the GTEx data. The levels of cis eQTL 
significance of each SNP-gene pair in a given brain region (Y-axis) were plotted against 
corresponding normalized effect sizes (i.e., beta on X-axis). A vertical and a horizontal grey 
dashed line, respectively represent a slope of zero and nominal significance of 0.05. 
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Table S1. Genotype of replication samples.
ID Residual age at onsetrs113605276rs1146382rs115068682rs45576236rs3820400rs10159075rs75376497
fluidigm.1 0.4320 C C C T C T A A A G A G G G
fluidigm.2 3.3616 C C C T T T A G A G A A G G
fluidigm.3 -9.7580 C C T T T T A A G G A A G G
fluidigm.4 16.2420 C C C T T T A A A G A G G G
fluidigm.5 1.6159 C C C T T T A G A G A G G G
fluidigm.6 10.1557 C C C T T T A A A G A A G G
fluidigm.7 2.2804 C C C T T T A A A G A A C G
fluidigm.8 14.0958 C C C T C T A A G G A A G G
fluidigm.9 16.3177 C C T T T T A G G G A A G G
fluidigm.10 -10.6384 C C C T T T A G G G A A G G
fluidigm.11 0.0847 C T T T T T A A G G A G G G
fluidigm.12 2.6159 C C T T T T A A G G A A G G
fluidigm.13 5.0847 C C C T T T A G A G A A C G
fluidigm.14 0.6159 C C T T T T A A A A A A G G
fluidigm.15 7.2804 C C T T T T A A G G A G G G
fluidigm.16 -6.6823 C C C T C T A A A G A A G G
fluidigm.17 1.8897 C C C C T T A G G G A A G G
fluidigm.18 1.3616 C C C C T T A A A G A A G G
fluidigm.19 -0.7196 C C C T T T A G A G A A G G
fluidigm.20 5.8345 C C T T T T A A A G A A G G
fluidigm.21 4.1885 C C C C T T A A A G A A G G
fluidigm.22 -7.8115 C C C T T T A A G G A A G G
fluidigm.23 6.4320 C C T T T T A G A G A G C G
fluidigm.24 -3.3841 C C C T T T A A A G A A C G
fluidigm.25 6.2420 C C T T T T A A A G A G G G
fluidigm.26 6.2420 C T T T T T A A A A A A G G
fluidigm.27 -1.6384 C C C T T T A A G G A A G G
fluidigm.28 -0.3841 C C T T T T A A A A A A G G
fluidigm.29 14.2804 C C C T C T A A G G A A G G
fluidigm.30 -3.1103 C C T T T T A G G G A A G G
fluidigm.31 11.2420 C C C T T T A A A G A A G G
fluidigm.32 12.3177 C C C T T T A A G G A A G G
fluidigm.33 -21.6823 C C C T T T A A A G A A G G
fluidigm.34 -16.1103 C C T T T T A G A G A G G G
fluidigm.35 -2.5680 C C C T C T A A A A A A G G
fluidigm.36 -5.6823 C C T T T T A A G G A A G G
fluidigm.37 8.8897 C C C T T T A A A G A A G G
fluidigm.38 -2.0313 C C C T C T A G A A A A G G
fluidigm.39 -4.9042 C C T T T T G G G G A G C G
fluidigm.40 -6.1103 C C C C T T A G G G A A G G
fluidigm.41 -3.6823 C C C T T T A G A A A A G G
fluidigm.42 9.3177 C C C T T T A G G G A A G G
fluidigm.43 14.3177 C T C C C T A A A G A G G G
fluidigm.44 6.1557 C C C T T T G G A G A A G G
fluidigm.45 5.8897 C C T T T T A A A G A G G G
fluidigm.46 -7.7580 C C C T T T A A A G A G G G
fluidigm.47 4.8897 C C C T T T A G G G A G G G
fluidigm.48 -5.1103 C C C C T T A G A G A A G G
fluidigm.49 4.0958 C T C C C T A A G G A A G G
fluidigm.50 -8.6384 C C C T T T A A G G A A G G
fluidigm.51 -5.6384 C C C C T T A A G G A A G G
fluidigm.52 -2.7196 C C T T C T A A A G A A G G
fluidigm.53 -13.7580 C C C C T T A A G G A A G G
fluidigm.54 6.8897 C C T T T T A G G G A A G G
fluidigm.55 -3.7196 C C C C T T A A A G A G G G
fluidigm.56 -1.6823 C C C T T T A G A A A A G G
fluidigm.57 7.4671 C C C T T T A A A A A A G G
fluidigm.58 7.3177 C C C T T T A A A G A A G G
fluidigm.59 2.2420 C T C T T T A A A G A A G G
fluidigm.60 -1.7196 C C T T T T A A G G A A G G
fluidigm.61 -7.7580 C C T T T T A A A G A A C G
fluidigm.62 -7.7196 C T C T T T A G A G A A G G
fluidigm.63 -1.9153 C C T T T T A A A G A G G G
fluidigm.64 1.4671 C C C T T T A A G G A A G G
fluidigm.65 -0.5680 C C C C T T A A G G A A G G
fluidigm.66 -4.7580 C C T T T T A A G G A A G G
fluidigm.67 1.2804 C C T T T T A G G G A A G G
fluidigm.68 0.2804 C C C C T T A A A A A A G G
fluidigm.69 -4.1103 C C T T T T A A A G A A G G
fluidigm.70 1.2420 C C T T T T A A G G A A G G
fluidigm.71 6.4320 C C T T T T A A A G A A G G
fluidigm.72 0.3616 C C C T T T G G A G A A G G
fluidigm.73 -1.9153 C C T T T T A A A A A A G G
fluidigm.74 -8.5680 C C C T T T A G A G A A G G
fluidigm.75 5.2420 C C T T T T A G G G A G G G
fluidigm.76 2.8897 C C C C T T A A A G A A G G
fluidigm.77 2.4320 C C T T T T A A G G A A G G
fluidigm.78 -2.7580 C C C T C T A G A G A A G G
fluidigm.79 0.8897 C C C T T T A G G G A A G G
fluidigm.80 -1.5680 C C C T T T A A A A A A G G
fluidigm.81 -2.3841 C C C T T T A A G G A A C G
fluidigm.82 3.2420 C C C T T T A A A G A A G G
fluidigm.83 4.0847 C C T T T T A A A G A A G G
fluidigm.84 6.0958 C C C T T T A G A G A A C G
fluidigm.85 2.3177 C C C C T T A A A G A A G G
fluidigm.86 1.3177 C T C T T T A A A A A A G G
fluidigm.87 6.4320 C C C C T T A A G G A A G G
fluidigm.88 3.0958 C T C T T T A A G G A A G G
fluidigm.89 -7.6823 C C C T T T A A G G A A G G
fluidigm.90 0.0958 C C T T T T A A G G A A G G
fluidigm.91 -3.7580 C C C T T T G G G G A G G G
fluidigm.92 6.0958 C T T T T T A G A G A A G G
fluidigm.93 -17.7580 C C C C T T G G G G A A G G
fluidigm.94 -2.5680 C C T T T T A A A G A A G G
fluidigm.95 1.4320 C C C T T T A A A G A A G G
fluidigm.96 22.0958 C C C T T T A A A G A A G G
fluidigm.97 -4.5680 C C C T 0 0 A G A A A A G G
fluidigm.98 -0.6823 C C C T T T A A G G A A C G
fluidigm.99 4.4320 C C C C T T A A A G A G G G
fluidigm.100 0.8897 C C T T T T A A A G A A G G
fluidigm.101 3.0958 C C C T T T A G G G A A G G
fluidigm.102 9.8897 C C C C T T A G A G A A G G
fluidigm.103 -12.1103 C C C T T T A G G G A G G G
fluidigm.104 -5.5680 C C C T T T G G A G A A C G
fluidigm.105 7.2420 C C T T T T A A G G A A G G
fluidigm.106 -19.6823 C C C C T T A A G G A A G G
fluidigm.107 -11.1103 C C C T T T A G G G A G G G
fluidigm.108 3.8897 C C T T T T A A A G A A G G
fluidigm.109 11.6159 C C C C T T A G G G A G G G
fluidigm.110 -14.9042 C C C T 0 0 A G A A A A G G
fluidigm.111 -7.6384 C C T T T T A A G G A A G G
fluidigm.112 -6.7580 C C T T 0 0 A A G G A A G G
fluidigm.113 0.2420 C C T T T T A A A G A A G G
fluidigm.114 1.2804 C C C C T T A A A G A A G G
fluidigm.115 7.2420 C C T T T T A A A G A A G G
fluidigm.116 -0.1103 C C C T T T A G A G A A G G
fluidigm.117 -8.7580 C C C T T T A A G G A A G G
fluidigm.118 2.0958 C C T T T T A A G G A A G G
fluidigm.119 21.3177 C C T T T T A A A G A A G G
fluidigm.120 -9.7580 C T C C T T A A A G A A G G
fluidigm.121 -0.3841 C C C C T T A A G G A A G G
fluidigm.122 5.2420 C C C T T T A G A G A A G G
fluidigm.123 8.2804 C C C T T T A A A G A G G G
fluidigm.124 -7.1103 C C C T 0 0 A A A A A A G G
fluidigm.125 -0.7196 C C T T T T A A A G A G G G
fluidigm.126 -0.5680 C C T T T T G G A G A A G G
fluidigm.127 -5.1103 C C C T T T A A A G A A G G
fluidigm.128 -10.9042 C C T T 0 0 A A A A A A G G
fluidigm.129 -9.9042 C C C T T T A G A A A A C G
fluidigm.130 -0.0313 C C C T 0 0 A A G G A A G G
fluidigm.131 -6.6823 C C T T T T A A G G A A G G
fluidigm.132 -4.1103 C C C C T T A G A G A A C G
fluidigm.133 -3.6823 C C C T 0 0 A G A G A A G G
fluidigm.134 -21.1103 C C T T T T A G G G A A C G
fluidigm.135 2.2420 C C T T T T A A G G A A G G
fluidigm.136 -6.9042 C C C T T T A A A A A A G G
fluidigm.137 -10.6823 C T C T T T A A A G A G C G
fluidigm.138 -1.3841 C C T T T T A G G G A A C G
fluidigm.139 5.4320 C C T T T T A A A G A A G G
fluidigm.140 1.9687 C C T T T T A G A G A A G G
fluidigm.141 4.8897 C C T T T T A A A A A A C G
fluidigm.142 -6.5680 C C C T T T A G A A A A G G
fluidigm.143 -14.1103 C C T T T T A A A G A A G G
fluidigm.144 -12.6823 C C C T T T G G A G A A G G
fluidigm.145 -2.9042 C C C C T T A G G G A A G G
fluidigm.146 4.3177 C C T T T T A A G G A G G G
fluidigm.147 -0.7580 C C C T T T A G A A A A G G
fluidigm.148 -2.5680 C C C C T T A A A A A A G G
fluidigm.149 -10.7580 C C C T T T A A A G A A C G
fluidigm.150 4.4320 C C C T T T A A A A A A G G
fluidigm.151 -2.9042 C C T T T T G G G G A A G G
fluidigm.152 -3.9153 C C T T T T A A A G A A G G
fluidigm.153 9.8897 C C C T T T A G A G A A G G
fluidigm.154 0.0847 C C C T T T A A A A A A G G
fluidigm.155 -18.9042 C C C C T T A A A G A A G G
fluidigm.156 -0.6384 C C T T T T A A A A A A G G
fluidigm.157 2.1885 C C T T T T A G A A A A G G
fluidigm.158 -9.9042 C C C T C T A G A G A A G G
fluidigm.159 1.3177 C C C T T T A A G G A A G G
fluidigm.160 -14.7580 C C C T T T A A G G A A G G
fluidigm.161 -2.7196 C C T T T T A G G G A A G G
fluidigm.162 1.8897 C C C C C T A A A G A G G G
fluidigm.163 3.2420 C C T T T T A A A G A A G G
fluidigm.164 -4.0313 C C C T T T A G G G A A G G
fluidigm.165 -6.3841 C C C T T T A A G G A G G G
fluidigm.166 -8.9042 C C C C T T A A A G A A G G
fluidigm.167 1.4671 C C C T T T A A A A A A G G
fluidigm.168 -3.7196 C C C C T T A A A G A A G G
fluidigm.169 2.8897 C C C T T T A A G G A A G G
fluidigm.170 -17.5680 C C C T T T A G G G A A G G
fluidigm.171 -5.9042 C C T T T T A A A A A A G G
fluidigm.172 -0.7196 C C C C T T A G A A A A G G
fluidigm.173 6.2420 C C C T T T A A A A A A G G
fluidigm.174 -12.9042 C C C T T T A A G G A G G G
fluidigm.175 0.8897 C C C T T T A A G G A A G G
fluidigm.176 14.6159 C T T T T T A A G G A A G G
fluidigm.177 -1.0313 C C C T T T A A G G A G G G
fluidigm.178 -8.1103 C C C T T T A G G G A A G G
fluidigm.179 12.0958 C C T T T T A A G G A A G G
fluidigm.180 -5.7580 C C T T T T A G G G A A G G
fluidigm.181 2.2420 C T C T T T A A G G A A G G
fluidigm.182 -4.6823 C C C T T T A G A A A A G G
fluidigm.183 -6.5680 C C C T T T A A A G A A G G
fluidigm.184 0.0847 C C C T T T A A A G A A G G
fluidigm.185 -2.7196 C C C T T T A A A G A A G G
fluidigm.186 3.9687 C C C C T T A A G G A G G G
fluidigm.187 -4.1103 C C C T T T A A A A A G G G
fluidigm.188 7.0958 C C C T T T A A A G A A G G
fluidigm.189 8.2420 C C T T T T A G G G A A G G
fluidigm.190 8.2804 C C C T T T A A G G A A G G
fluidigm.191 -1.7196 C C C T T T A A A G A A G G
fluidigm.192 -6.6823 C C C T T T A G A G A G G G
fluidigm.193 10.4320 C C C T T T A A A G A A G G
fluidigm.194 1.3616 C C C T T T A G G G A A G G
fluidigm.195 -7.5680 C C C T T T A A A G A A G G
fluidigm.196 -5.7196 C C C T C T A A A G A A G G
fluidigm.197 2.2804 C C C T T T A A G G 0 0 G G
fluidigm.198 -1.6384 C C C T T T A A A G A A C G
fluidigm.199 0.4320 C C C T T T A A G G A A G G
fluidigm.200 2.8897 C C C T T T A A A G A G G G
fluidigm.201 15.2804 C C C T T T A A A G A A G G
fluidigm.202 0.8897 C T T T T T A G A G A G G G
fluidigm.203 -2.7580 C T T T T T A A G G A A G G
fluidigm.204 2.1557 C C C T T T A A A G A A C G
fluidigm.205 -2.6823 C C C T T T A A A A A A G G
fluidigm.206 -2.5680 C C C C T T A A G G A A G G
fluidigm.207 11.8897 C C T T T T A G A A A G G G
fluidigm.208 -0.6384 C C C T T T A G G G A A 0 0
fluidigm.209 9.3177 C C T T T T A G A G A A G G
fluidigm.210 14.8897 C T T T T T A G 0 0 A G G G
fluidigm.211 4.1557 C C T T T T A A A G 0 0 G G
fluidigm.212 4.8897 C C T T T T A A A G A A G G
fluidigm.213 -1.1103 C T C T T T A A G G A A G G
fluidigm.214 -1.6384 C C T T T T A A A G A A G G
fluidigm.215 -8.1103 C T C T T T A A A G A A G G
fluidigm.216 1.2420 C C C T T T A A G G A A G G
fluidigm.217 6.0958 C C C C T T A G G G A A G G
fluidigm.218 9.8345 C C C T T T A G G G A A G G
fluidigm.219 -9.7580 C C T T T T A A A G A G G G
fluidigm.220 8.2804 C C T T T T A A G G A A G G
fluidigm.221 -8.6384 C C C T T T A A G G A A G G
fluidigm.222 5.8897 C C C C T T A A A G A A G G
fluidigm.223 4.8897 C C C C T T G G G G A A G G
fluidigm.224 -0.7580 C C C C T T A G G G A G G G
fluidigm.225 7.3177 C T C T C T A G A G A A G G
fluidigm.226 -14.1103 C C T T T T A A A G A A G G
fluidigm.227 -0.1103 C C T T T T A G A G A A G G
fluidigm.228 -1.9153 C C T T T T A A A G A A G G
fluidigm.229 -3.5680 C C T T T T A A G G A A G G
fluidigm.230 3.2420 C T C T T T A A A G A A C G
fluidigm.231 9.3177 C C C C T T A A G G A A G G
fluidigm.232 -1.5680 C C T T T T A A G G A A G G
fluidigm.233 -15.9042 C C C T T T A G A G A G G G
fluidigm.234 4.2804 C C C C T T A A A G A A G G
fluidigm.235 4.2804 C C C C C T A A A A A A G G
fluidigm.236 5.3177 C C C C T T A G G G A A G G
fluidigm.237 -2.6384 C C C C T T A G G G A A C G
fluidigm.238 6.0847 C C T T T T A A G G A G G G
fluidigm.239 3.0847 C C C T T T A G A G A A G G
fluidigm.240 0.2804 C T C T T T A A A G A A C G
fluidigm.241 -14.7580 C C C T T T A A A G A G G G
fluidigm.242 -2.7196 C C C T T T A G G G A G G G
fluidigm.243 2.1557 C C T T T T A G G G A A G G
fluidigm.244 13.2420 C C C T T T A G A A A A C G
fluidigm.245 -28.9042 C C C T T T A G G G A A G G
fluidigm.246 6.2420 C T C T T T A A A G A G G G
fluidigm.247 5.1885 C C C T C T A G A A A A G G
fluidigm.248 3.2804 C C C T T T A A A G A A G G
fluidigm.249 3.8897 C C T T T T A G A G A G G G
fluidigm.250 -1.9153 C C T T T T A A A G A A G G
fluidigm.251 -1.6823 C C C C T T A A A G A A G G
fluidigm.252 2.2804 C C T T T T A A A A A A G G
fluidigm.253 3.2420 C C C T T T A A G G A A G G
fluidigm.254 -8.6384 C T C C T T A A A G A G G G
fluidigm.255 0.4320 C C C T T T A A G G A A G G
fluidigm.256 -24.1103 C C C T T T A A A G A A G G
fluidigm.257 -19.9042 C C C C T T A A G G A A G G
fluidigm.258 -8.9153 C C C C T T A A G G A A G G
fluidigm.259 -4.7580 C C C T T T A G A G A A G G
fluidigm.260 0.2420 C C T T T T A G G G A A C G
fluidigm.261 -0.6384 C C C T T T A A G G A G G G
fluidigm.262 0.0958 C C C T T T A A A G A A G G
fluidigm.263 3.8897 C C T T C T A A G G A G G G
fluidigm.264 -10.1103 C C C T T T A A A G A A G G
fluidigm.265 10.4320 C C C C T T A G A G A A G G
fluidigm.266 4.2804 C C T T T T A A A G A A C G
fluidigm.267 -8.9042 C C C C T T A A A A A A G G
fluidigm.268 2.2804 C C C T T T A A G G A A G G
fluidigm.269 12.0958 C C T T T T A A G G A A C G
fluidigm.270 -3.3841 C C C T T T A G A G A A C G
fluidigm.271 -1.7580 C C T T T T A A A A A A G G
fluidigm.272 8.3177 C C C T T T A A G G A A G G
fluidigm.273 1.8897 C C C T T T A G A A A G G G
fluidigm.274 -0.1103 C C C T T T A A G G A G G G
fluidigm.275 2.3177 C C C T T T A A A G A A C G
fluidigm.276 0.3616 C C T T T T A G A G A G G G
fluidigm.277 6.4320 C T C T T T A G G G A A G G
fluidigm.278 11.0958 C C T T T T A A A G A G G G
fluidigm.279 4.8897 C C C T T T A A A G A A C G
fluidigm.280 0.3177 C C C C T T A A G G A A G G
fluidigm.281 -2.7580 C C T T C T A G G G A A G G
fluidigm.282 1.8897 C C C T T T A A A A A A G G
fluidigm.283 -8.1103 C C C C T T A G A G A G G G
fluidigm.284 11.3616 C C T T T T A G A A A A C G
fluidigm.285 1.2804 C T C T C T A G A G A A G G
fluidigm.286 -1.7580 C C C T T T A A A G A A G G
fluidigm.287 6.9687 C C C C T T A G G G A A G G
fluidigm.288 5.9687 C C C C T T A A G G A G G G
fluidigm.289 4.4320 C C C T T T A G A G A A G G
fluidigm.290 3.3177 C C C T T T A A G G A A G G
fluidigm.291 -2.7196 C C T T T T A G A G A A G G
fluidigm.292 -6.1103 C C C T T T A G A G A G G G
fluidigm.293 -0.7580 C C C C T T A A A G A A G G
fluidigm.294 -1.5680 C C T T T T A G A G A A G G
fluidigm.295 -8.6823 C C T T T T A A G G A A G G
fluidigm.296 3.2420 C C T T T T A A A A A A G G
fluidigm.297 -1.9153 C C C T T T A A G G A A G G
fluidigm.298 2.1885 C C T T T T A G A A A A G G
fluidigm.299 0.3177 C C C C T T A A A A A A G G
fluidigm.300 -2.6823 C C C T T T A A A G A G G G
fluidigm.301 3.2420 C C C T T T A A A A A A G G
fluidigm.302 -9.1103 C C C C T T A A A A A A G G
fluidigm.303 4.3177 C C C T T T A A A G A G G G
fluidigm.304 0.2804 C C T T T T A A G G 0 0 G G
fluidigm.305 5.4320 C C 0 0 T T A A G G 0 0 G G
fluidigm.306 0.0781 C C C T T T A A G G A A G G
fluidigm.307 1.8897 C C C C T T G G A A A A G G
fluidigm.308 -6.1103 C C C C T T A A A G A G G G
fluidigm.309 10.4320 C C C C T T A A G G A A G G
fluidigm.310 -2.9153 C C C T T T A A A A A A G G
fluidigm.311 13.3177 C C T T T T A A A G A A G G
fluidigm.312 1.4320 C C C T T T A A G G A A G G
fluidigm.313 4.4320 C T C T T T A A A G A A G G
fluidigm.314 12.0958 C C T T T T A G G G A A G G
fluidigm.315 2.8897 C C T T T T A G A A A A G G
fluidigm.316 1.0847 C C C T T T A A G G A A G G
fluidigm.317 -6.7580 C C C T T T A A A A A G G G
fluidigm.318 -24.1103 C C C T T T A G A G A A G G
fluidigm.319 -3.6823 C C C C T T A G A G A A C G
fluidigm.320 1.9847 C C C T T T A A A G A G G G
fluidigm.321 3.2420 C C T T T T A G A A A A G G
fluidigm.322 -18.9153 C C C T T T A A G G A A G G
fluidigm.323 3.2420 C C T T T T A G G G A A C G
fluidigm.324 -0.7580 C T C T T T A A G G A G G G
fluidigm.325 0.3177 C C C T T T A A G G G G C G
fluidigm.326 -2.7580 C C T T T T A A G G A A G G
fluidigm.327 4.0781 C C T T T T A G A G G G G G
fluidigm.328 -2.7196 C C C C T T A G A A A A G G
fluidigm.329 -11.5680 C C C T T T A G G G A A G G
fluidigm.330 6.2804 C C C C T T A G A A A G G G
fluidigm.331 8.3177 C C T T T T A A G G A G G G
fluidigm.332 6.8897 C C T T T T A A A G A A G G
fluidigm.333 -1.7580 C C C T C T A A A G A A G G
fluidigm.334 -0.9153 C C C T T T A A A G A A G G
fluidigm.335 -2.7196 C C T T C T A A A G G G G G
fluidigm.336 -3.6823 C C C T T T A A G G A A G G
fluidigm.337 10.3177 C C C C T T A A G G A A G G
fluidigm.338 -17.6823 C C C T T T A A A G A A C G
fluidigm.339 3.6159 C C T T T T A A A G A A G G
fluidigm.340 1.2804 C C T T T T A G A G A A G G
fluidigm.341 -4.6823 C C C C T T A G A A A A G G
fluidigm.342 6.4320 C C T T T T A A A G A A G G
fluidigm.343 0.3616 C C T T T T A A G G A A G G
fluidigm.344 1.2420 C T C T T T A A G G A G G G
fluidigm.345 11.3616 C C T T T T A A A G A A G G
fluidigm.346 -6.7580 C T C T T T G G A A A A G G
fluidigm.347 -5.7580 C C T T T T A A A G A A G G
fluidigm.348 -1.0313 C C C T T T A A A G A A G G
fluidigm.349 2.3177 C C T T T T A G G G A A G G
fluidigm.350 9.6159 C C C T T T A G A A A A G G
fluidigm.351 -2.9153 C C C C T T A A G G A A G G
fluidigm.352 -4.7580 C T T T C T A A A A A A G G
fluidigm.353 -1.6823 C C C T T T A A G G A A G G
fluidigm.354 -2.9153 C C C T T T A G G G A G G G
fluidigm.355 17.0847 C C T T T T A A A G A A G G
fluidigm.356 5.6159 C C C T T T A A G G A A G G
fluidigm.357 1.0958 C C T T T T A A A G A A G G
fluidigm.358 1.3177 C C C T T T A A A G A G G G
fluidigm.359 -6.7580 C C C T T T A A G G A A G G
fluidigm.360 2.4320 C C C T T T A G G G A A G G
fluidigm.361 -7.6384 C C C T T T A A A G A A C G
fluidigm.362 0.8897 C C C C T T A A A A A A C G
fluidigm.363 7.8897 C T T T T T A G A G A A G G
fluidigm.364 0.2420 C C 0 0 T T A A A G 0 0 G G
fluidigm.365 -10.9042 C C C T T T A A G G 0 0 G G
fluidigm.366 1.3616 C C T T T T A A A A G G G G
fluidigm.367 13.2804 C C C C T T G G A G A A C G
fluidigm.368 -13.7196 C C T T T T A G A G A A G G
fluidigm.369 -0.5680 C C C T T T A A G G A A G G
fluidigm.370 12.2420 C T T T 0 0 A A A A A G G G
fluidigm.371 12.3177 C C C T T T A G 0 0 A G G G
fluidigm.372 -7.6823 C C T T T T A A A G A G G G
fluidigm.373 7.4320 C C T T T T A A A G A A G G
fluidigm.374 13.2804 C C C C T T A A G G A A G G
fluidigm.375 4.8897 C C T T T T A A A G A G G G
fluidigm.376 0.4320 C C C T T T A G G G A A G G
fluidigm.377 2.8897 C C C T T T A A G G A A C G
fluidigm.378 -3.7196 C C C C T T A A G G A A G G
fluidigm.379 -11.5680 C T C T T T A A A G A A G G
fluidigm.380 -5.9042 C C C T T T A A A A A A G G
fluidigm.381 0.4320 C C T T T T A A G G A A G G
fluidigm.382 -8.1103 C C C T T T A A A A A A G G
fluidigm.383 3.3616 C C C T T T A A A G A G G G
fluidigm.384 8.9687 C C C T T T A A A A A A G G
fluidigm.385 -5.6384 C T C T T T A G A G A A G G
fluidigm.386 8.6159 C C T T T T A A A A A A G G
fluidigm.387 -6.7196 C C C C C T A A G G A G G G
fluidigm.388 -5.0313 C C T T C T A A A G A A G G
fluidigm.389 -8.5680 C C C T T T A A A G A A G G
fluidigm.390 -1.7196 C C C T T T A A G G A A C G
fluidigm.391 8.2420 C C T T T T A A G G A A G G
fluidigm.392 -1.1103 C T T T T T A G A G A A G G
fluidigm.393 1.8897 C T C T T T A A A A A A C G
fluidigm.394 5.0958 C C C C T T A A A G A A G G
fluidigm.395 6.3177 C C T T C T A G G G A A C G
fluidigm.396 8.3177 C C C T C T A G A G A A G G
fluidigm.397 -14.0313 C C C C C T A A A G A A G G
fluidigm.398 7.3616 C C C T T T A G G G A A G G
fluidigm.399 -8.7196 C C C T T T A G G G A G G G
fluidigm.400 8.6159 C C C C T T A A A G A A G G
fluidigm.401 -19.5680 C C C T T T A A G G A A G G
fluidigm.402 8.3177 C C C T T T A G A G A A G G
fluidigm.403 2.6159 C C C T C T A A A A A A G G
fluidigm.404 -5.0313 C C C C T T A G G G A A G G
fluidigm.405 -1.7196 C C C T T T A A A G A A G G
fluidigm.406 0.4320 C C T T T T A G A G A G G G
fluidigm.407 -3.0313 C C C T T T A A A G A G G G
fluidigm.408 -6.7580 C C C T T T A A A G A A G G
fluidigm.409 -5.3841 C C C T T T A A G G A G G G
fluidigm.410 -5.1103 C C T T T T G G G G A A G G
fluidigm.411 14.0847 C C C C T T A G G G A A G G
fluidigm.412 4.3177 C C C T T T A A A A A A G G
fluidigm.413 5.0958 C C C T T T A A A G A A G G
fluidigm.414 4.2420 C C C T T T A A A A A G G G
fluidigm.415 0.6159 C C C T T T A G A G A G G G
fluidigm.416 8.1557 C C T T T T A A A A A A G G
fluidigm.417 -18.5680 C C C T T T A G G G A A G G
fluidigm.418 3.2420 C C C T T T G G A G A A G G
fluidigm.419 4.3616 C T C T T T A A A G A A G G
fluidigm.420 6.0781 C C C C T T A A A G A A G G
fluidigm.421 5.3616 C C C T T T A A A G A A G G
fluidigm.422 3.2804 C C T T C T A A A G A A G G
fluidigm.423 4.6159 C C C T T T A A G G A A G G
fluidigm.424 9.3616 C C C T T T A G A G A A G G
fluidigm.425 -12.7196 C C C T T T A A A A A A G G
fluidigm.426 2.2420 C C C T T T A G G G A A G G
fluidigm.427 1.1557 C T C T T T A G A G A G G G
fluidigm.471 4.1557 C C C T T T A A A G A A G G
fluidigm.472 17.3177 C C T T T T A A G G A G G G
fluidigm.473 10.3177 C C C T T T A A A G A A G G
fluidigm.474 0.2804 C C C T T T A G G G A A G G
fluidigm.475 -4.6384 C C C T T T A G A G A A G G
fluidigm.476 -14.7196 C C T T T T A A A A A A G G
fluidigm.477 -3.3841 C C C T T T A G A G A G G G
fluidigm.478 3.8897 C T T T T T A A A G A A G G
fluidigm.479 -10.7580 C C C T T T A G G G A A G G
fluidigm.480 4.8897 C C T T T T A A A G A A G G
fluidigm.481 -2.1103 C C C T T T G G G G A G G G
fluidigm.482 -5.6823 C T C T T T A G G G A A G G
fluidigm.483 13.0958 C C T T T T A G G G A A G G
fluidigm.484 -4.1103 C C C C T T A A A G A A G G
fluidigm.485 -1.1103 C C C T T T A A G G A A G G
fluidigm.486 -0.6384 C C T T T T A A A G A A G G
fluidigm.487 7.4671 C C C T T T A A G G A A G G
fluidigm.488 -10.9042 C C C T T T A G A G A A G G
fluidigm.489 -0.5680 C C T T T T A A A G A G C G
fluidigm.490 9.0958 C C C T T T A A G G A A G G
fluidigm.491 -5.9042 C C C C T T A A G G A A G G
fluidigm.492 -1.8443 C C C T T T A G A G A A G G
fluidigm.493 -18.7196 C C C T T T A A G G A A G G
fluidigm.494 5.3616 C C C T T T A A A A A A G G
fluidigm.495 -1.5680 C C T T T T A A A G A A G G
fluidigm.496 -6.7580 C C T T T T A A A G A A G G
fluidigm.497 5.0958 C C T T T T A A A G A A G G
fluidigm.498 -1.9153 C C T T T T G G A A A A G G
fluidigm.499 -2.3841 C C C T T T A A A G A A G G
fluidigm.500 -2.6823 C C C C T T A A G G A G G G
fluidigm.501 -10.6823 C C C T T T A A A G A A G G
fluidigm.502 -6.7580 C T T T C T A A A G A A G G
fluidigm.503 5.2420 C C C T T T A A A G A G G G
fluidigm.504 7.2420 C C C T T T A G A G A G G G
fluidigm.505 4.6159 C C C T T T A A G G A A G G
fluidigm.506 -1.7580 C C C T T T A A A G A G G G
fluidigm.507 8.3177 C C C T T T A G G G A G G G
fluidigm.508 -11.6823 C C T T T T A A A G A A G G
fluidigm.509 -14.1103 C C C C T T A A G G A A C G
fluidigm.510 -1.6384 C C C T T T A A G G A A G G
fluidigm.511 -0.9219 C C C T T T A G G G 0 0 G G
fluidigm.512 2.2804 C C C T T T A A A A A A G G
fluidigm.513 -7.7580 C C C T T T A A G G A A G G
fluidigm.514 -10.7196 C C T T T T A A G G A G G G
fluidigm.515 9.2420 C C T T T T A G A G A A G G
fluidigm.516 6.8897 C C T T T T A A G G A A G G
fluidigm.517 -3.6823 C C C T T T A A G G A G G G
fluidigm.518 3.2420 C T C C T T A G A G A A G G
fluidigm.519 1.3616 C C C T T T A A A G A G G G
fluidigm.520 -4.5680 C C C T T T A A A G A G G G
fluidigm.521 2.4320 C C T T T T A A G G A A G G
fluidigm.522 -5.6823 C C C T T T A A A A A A G G
fluidigm.523 -9.6823 C C C T T T A G A G A G C G
fluidigm.524 3.0958 C C C C T T A A G G A A C G
fluidigm.525 -0.5680 C C C C T T A G A A A A C G
fluidigm.526 1.2420 C C T T T T G G A A A A G G
fluidigm.527 7.1557 C C C T T T A A A G A A G G
fluidigm.528 6.2420 C C C T T T A G G G A A G G
fluidigm.529 4.2420 C C C C T T A A A G A A G G
fluidigm.530 9.2420 C C C T T T A A A G A A G G
fluidigm.531 -10.1103 C C T T T T A G A G A A G G
fluidigm.532 2.8897 C C C T T T A G G G A G G G
fluidigm.533 -4.7580 C C C T T T A A A G A A G G
fluidigm.534 10.8897 C C C T T T A A A G A A G G
fluidigm.535 7.3177 C C C T T T A G A G 0 0 G G
fluidigm.536 4.0847 C T T T C T A G G G 0 0 G G
fluidigm.537 12.0958 C C C T T T A G A G A A G G
fluidigm.538 5.9847 C C C C T T A G G G A A G G
fluidigm.539 8.2420 C C C C T T A G 0 0 A A G G
fluidigm.540 4.0781 C C C T T T A G G G A A G G
fluidigm.541 5.8897 C T C T T T A G A G A A G G
fluidigm.542 -5.6384 C C C T T T A A A G A G G G
fluidigm.543 1.6159 C C C T C T A A G G A G G G
fluidigm.544 -1.7580 C C C T T T A A A A A A G G
fluidigm.545 -0.9042 C C C T T T A G A A A A G G
fluidigm.546 3.6159 C C C T T T A A G G A A G G
fluidigm.547 6.4320 C C T T T T A A G G 0 0 G G
fluidigm.548 -5.7580 C C C T T T A A A G A A G G
fluidigm.549 4.2420 C C C T T T A G G G A A G G
fluidigm.550 0.2804 C C T T T T A A G G A A G G
fluidigm.551 11.3177 C C C T T T A G G G A A G G
fluidigm.552 5.3177 C C T T T T A A G G A A G G
fluidigm.553 8.2420 C C C T T T A A G G A G G G
fluidigm.554 -4.1103 C C T T 0 0 A A G G A A G G
fluidigm.555 3.2804 C C C T T T A A A G A A G G
fluidigm.556 6.4320 C C C T T T A A G G A A G G
fluidigm.557 -0.7196 C C T T T T A A A G A G G G
fluidigm.558 2.2420 C C C T T T A A G G A A G G
fluidigm.559 0.0847 C C C T T T A A A G A G G G
fluidigm.560 -4.7196 C C T T T T A A G G A A G G
fluidigm.561 -5.9153 C C C T T T A G A G A G G G
fluidigm.562 7.2420 C C C T T T A A G G A A G G
fluidigm.563 -10.1103 C C C T T T A G A G A A G G
fluidigm.564 5.9847 C C C T T T A A G G A A G G
fluidigm.565 -9.5680 C C T T T T A A A G A A G G
fluidigm.566 2.2420 C C T T T T A A A G A A G G
fluidigm.567 0.2804 C C C T T T A A A G A A G G
fluidigm.568 -2.7580 C C C C T T A G A G A A G G
fluidigm.569 3.0958 C T C T T T A G A G A A G G
fluidigm.570 -14.6823 C C C T T T A A G G A A G G
fluidigm.571 -17.5680 C C C T T T A A G G A A G G
fluidigm.572 1.0958 C C C T T T A A A G A G G G
fluidigm.573 -11.7580 C C T T T T A G A G A A G G
fluidigm.574 -6.7580 C C T T T T A G A G A A G G
fluidigm.575 -1.7196 C C C T T T A A G G A A G G
fluidigm.576 11.2420 C C C T T T A A G G A A G G
fluidigm.577 7.4320 C C T T T T A A A G A A G G
fluidigm.578 -1.1103 C C C C T T A G G G A G G G
fluidigm.579 1.3616 C C C T T T A A A G A A G G
fluidigm.580 6.2420 C C C T T T A A A G A A G G
fluidigm.581 -16.5680 C C C C T T A G G G A A G G
fluidigm.582 5.6159 C C T T T T A A G G A A G G
fluidigm.583 3.0847 C C T T T T A A A G A G C G
fluidigm.584 -1.7196 C C T T T T A G A A A A G G
fluidigm.585 -0.6823 C C C T T T A A A A A A G G
fluidigm.586 16.0958 C C C T T T A A G G A A G G
fluidigm.587 6.0847 C T C C T T A A A G A A G G
fluidigm.588 1.2420 C T T T T T A A A A A A G G
fluidigm.589 1.3616 C C C T T T A A A G A G G G
fluidigm.590 4.4671 C T T T T T G G A A A A G G
fluidigm.591 3.8897 C C C C T T G G A G A A G G
fluidigm.592 2.3616 C C T T T T A G A G A A G G
fluidigm.593 12.1557 C C T T T T A A A G A A G G
fluidigm.594 3.8897 C C T T T T A G A A A A G G
fluidigm.595 2.0847 C C T T T T A A A G A A G G
fluidigm.596 4.2420 C C C T C T A G A G A A G G
fluidigm.597 -0.9042 C C C T T T A A A G A A G G
fluidigm.598 -6.7196 C C C C T T A A G G A A G G
fluidigm.599 4.2804 C T C T T T A A A G A A C G
fluidigm.600 -1.6384 C C T T T T A A G G A A G G
fluidigm.601 -1.1103 C C C C T T A A A G A G G G
fluidigm.602 -3.5680 C C C T T T A A A G A A G G
fluidigm.603 -5.6384 C C C C T T A A A A A A G G
fluidigm.604 10.3177 C C T T T T A A A G A G G G
fluidigm.605 -1.6384 C C C T T T A A A G A A G G
fluidigm.606 3.3177 C C T T T T A A A G A A G G
fluidigm.607 -7.5680 C C C C T T A A A A A A G G
fluidigm.608 -1.7580 C C T T T T G G A G A A G G
fluidigm.609 3.3177 C C T T T T A G G G A G G G
fluidigm.610 4.3177 C C T T T T A A A G A A G G
fluidigm.611 3.1885 C C C T T T A A A G A A G G
fluidigm.612 -3.1103 C C C T C T A A G G A A G G
fluidigm.613 -5.7580 C T C C C T A G A G A G G G
fluidigm.614 -12.1103 C C C T T T A G G G A A G G
fluidigm.615 -7.9042 C C T T T T A A G G A A G G
fluidigm.616 11.8897 C C T T T T A A A G A A G G
fluidigm.617 -3.6823 C C C T T T A A A G A A G G
fluidigm.618 9.8897 C C T T T T A A A G A A G G
fluidigm.619 -1.1103 C C C C T T A A G G A A G G
fluidigm.620 5.8897 C C C T T T A A A G A G G G
fluidigm.621 6.0847 C C C T T T A A A G A A G G
fluidigm.622 14.3616 C C T T T T A A 0 0 0 0 G G
fluidigm.623 3.0847 C C C C T T A A A G 0 0 G G
fluidigm.624 4.2420 C T T T T T A G A G A A G G
fluidigm.625 -2.9153 C C C C T T A A G G A A G G
fluidigm.626 0.2420 C C T T T T A A A G A A G G
fluidigm.627 10.9687 C C T T T T A A A G A A G G
fluidigm.628 -3.7196 C C C T T T A A G G A G G G
fluidigm.629 -1.5680 C C C T T T A G A A A A G G
fluidigm.630 3.3177 C C T T T T A A G G A A G G
fluidigm.631 -2.0313 C C C T T T A G A G A G C G
fluidigm.632 9.2804 C C C T T T A A A A A A G G
fluidigm.633 -2.7580 C C T T T T A A A G A A G G
fluidigm.634 -5.1103 C C C C C T A G G G A A G G
fluidigm.635 -0.9042 C C C C T T A A G G A A G G
fluidigm.636 0.3616 C T T T T T A A A G A A G G
fluidigm.637 -2.5680 C C C T T T A A A G A G G G
fluidigm.638 -0.5680 C C C T T T A A A G A G G G
fluidigm.639 12.2420 C C C T T T A A A G A A 0 0
fluidigm.640 3.6159 C T C T T T A G G G A G G G
fluidigm.641 11.2804 C C T T T T A A A G A G G G
fluidigm.642 1.1885 C C C T T T A G G G A A G G
fluidigm.643 -0.6823 C C T T T T A G A G A A G G
fluidigm.644 -6.1103 C C T T T T A G A A A A G G
fluidigm.645 -3.1103 C C C T T T A A 0 0 A A G G
fluidigm.646 -3.1103 C C C T T T A G G G A A G G
fluidigm.647 -6.5680 C C C C T T A G A G A G G G
fluidigm.648 -2.7580 C T C T T T A G G G A A G G
fluidigm.649 15.3177 C C T T T T A A A G A A G G
fluidigm.650 1.2804 C C T T T T A G A G A A G G
fluidigm.651 -0.1103 C C C T T T A A A G A A G G
fluidigm.652 3.3616 C C C T T T A A A G A A G G
fluidigm.653 23.0958 C T C T T T A A A G A A G G
fluidigm.654 -0.8115 C C C T T T A A A G A A G G
fluidigm.655 -7.8115 C T C C T T A A A G A A G G
fluidigm.656 3.3616 C T T T T T A A A G A G G G
fluidigm.657 -11.1103 C C C C T T A G A G A A G G
fluidigm.658 8.3177 C T C T T T A G A G A A G G
fluidigm.659 -13.3841 C C T T T T A G A G A G G G
fluidigm.660 6.1557 C C C C T T G G A G A A G G
fluidigm.661 -3.3841 C C T T T T A A G G G G G G
fluidigm.662 -10.1103 C C C T T T A A A A A A G G
fluidigm.663 2.2420 C C T T T T G G G G A A G G
fluidigm.664 5.8897 C C C T T T A A G G A A G G
fluidigm.665 -12.6823 C C C C T T A A A G A A G G
fluidigm.666 10.9687 C C T T T T A A A G A A G G
fluidigm.667 3.4320 C C T T T T A A A G A G G G
fluidigm.668 7.2804 C C T T T T A A G G A G G G
fluidigm.669 4.3616 C C C T T T A A A G A A C G
fluidigm.670 -3.9042 C C C C T T A G A G A A G G
fluidigm.671 8.2420 C C C T C T A A A A A A G G
fluidigm.672 5.9687 C C C T T T A A G G A A G G
fluidigm.673 23.9687 C C C T T T A A G G A A G G
fluidigm.674 1.9687 C C C T T T A A A G A G G G
fluidigm.675 -0.3841 C C C T T T A A A G A G G G
fluidigm.676 1.3177 C C C T T T A G A G A A G G
fluidigm.677 -4.7196 C C C T T T A A A G A A G G
fluidigm.678 -2.5680 C C C C T T A A A A A A G G
fluidigm.679 4.9687 C C C T T T A A A G A A G G
fluidigm.680 0.3177 C C C T T T A A G G A G G G
fluidigm.681 -8.7580 C C C C T T A A G G A A G G
fluidigm.682 17.8345 C C T T T T A G A G A A G G
fluidigm.683 1.2804 C C T T T T A A A G A A G G
fluidigm.684 3.0958 C T C T T T A A A G A A G G
fluidigm.685 5.8897 C C C T T T A A G G G G G G
fluidigm.686 2.3616 C C T T C T G G A G A A G G
fluidigm.687 -4.6823 C C T T T T A A G G A G G G
fluidigm.688 2.3177 C C C T T T A G A G A G C G
fluidigm.689 -17.9042 C C C T T T A A G G A A G G
fluidigm.690 -14.1103 C C C T T T A A A G A A C G
fluidigm.691 4.2804 C C T T T T A A G G A A G G
fluidigm.692 3.2420 C C C T C T A A G G A A G G
fluidigm.693 1.3616 C C C T T T A A G G A A G G
fluidigm.694 -15.1103 C C C C T T A A G G A G G G
fluidigm.695 -2.7196 C C C C C T A A G G A A G G
fluidigm.696 -4.6823 C C T T T T G G A G A A G G
fluidigm.697 2.6159 C C T T T T A G G G A A G G
fluidigm.698 -6.7580 C C T T T T A A A A A A G G
fluidigm.699 4.0958 C C T T T T A A A G A A G G
fluidigm.700 -1.0313 C C C T T T A A A G A A G G
fluidigm.701 -1.7196 C T C C C T A G A G A G G G
fluidigm.702 -6.1103 C C T T T T A G G G A A G G
fluidigm.703 2.8897 C C C T T T A G A G A A G G
fluidigm.704 1.3616 C C C T T T A A A G A G G G
fluidigm.705 -9.1103 C T C C T T A G A G A A G G
fluidigm.706 -10.7196 C T C C T T A G G G A G G G
fluidigm.707 -15.7580 C C C T T T A A A G A A G G
fluidigm.708 -7.9153 C C C T T T A G G G A A G G
fluidigm.709 4.2420 C C C T T T A A A A A G G G
fluidigm.710 2.4320 C C C T T T A A G G A A G G
fluidigm.711 -3.6384 C C C T T T A A A G A A G G
fluidigm.712 -0.5680 C C T T T T A A G G A A G G
fluidigm.713 7.8897 C C C T T T A A A A A A G G
fluidigm.714 2.9687 C C C T T T A A G G A A G G
fluidigm.715 9.3177 C C C T T T G G G G A A G G
fluidigm.716 1.2420 C C C T T T A G G G A A G G
fluidigm.717 1.4320 T T T T T T A G A A A A G G
fluidigm.718 1.2420 C C C T T T A A A G A A G G
fluidigm.719 1.8897 C C C C T T A A A A A A G G
fluidigm.720 3.0958 C C C T T T A A A G A A G G
fluidigm.721 -4.9042 C C C T T T A A G G A A G G
fluidigm.722 13.3177 C C C T T T A A G G A A G G
fluidigm.723 2.6159 C C C C T T A A A A A G G G
fluidigm.724 0.2420 C C C T T T A A A G A A C G
fluidigm.725 12.8897 C C C T T T A G A G A A G G
fluidigm.726 -1.7196 C C T T T T A A A G A A G G
fluidigm.727 2.4320 C C T T T T A A A G A A G G
fluidigm.728 -5.6823 C C T T C T A G G G A A G G
fluidigm.729 -7.1103 C C C T T T A G A A A G G G
fluidigm.730 2.1885 C C C T T T A G G G A A G G
fluidigm.731 2.8897 C C C T T T A A G G A A G G
fluidigm.732 0.3177 C C C T T T A A G G A A G G
fluidigm.733 -0.5329 C C C C C T A A A A A A 0 0
fluidigm.734 1.2804 C C C C T T A A G G A G C G
fluidigm.735 -7.7580 C C C T T T A G G G A A G G
fluidigm.736 1.2804 C C T T T T A A G G A A G G
fluidigm.737 -0.7196 C C T T T T A A G G A A G G
fluidigm.738 12.3616 C C C T T T A A A A A G G G
fluidigm.739 0.0958 C C T T T T A A A A A A G G
fluidigm.740 -12.1103 C C C T T T A A A G A A G G
fluidigm.741 2.6159 C C C T T T A G A G A G G G
fluidigm.742 -6.5680 C T C T T T A G A G A G G G
fluidigm.743 7.8897 C C T T T T A A A G A A G G
fluidigm.744 5.2420 C C C T T T A G A A A A G G
fluidigm.745 -1.7580 C C T T T T A G G G A A G G
fluidigm.746 -1.1103 C C C T T T A A G G A A G G
fluidigm.747 -2.1103 C C T T T T A A A G A A G G
fluidigm.748 -6.7196 C C T T T T A A G G A A G G
fluidigm.749 4.0847 C C C T C T A A A A A G G G
fluidigm.750 0.1557 C C C T T T A G G G A A G G
fluidigm.751 -7.6384 C C C T C T A A G G A A C G
fluidigm.752 3.0847 C C T T T T A G A G A A G G
fluidigm.753 4.0958 C C C T T T A A G G A G G G
fluidigm.754 -3.7580 C T T T T T G G A A A A G G
fluidigm.755 -6.6823 C C C C T T A A A G A A G G
fluidigm.756 1.4320 C C T T T T A G A A A G G G
fluidigm.757 1.4320 C C C C T T A A A A A A G G
fluidigm.758 -8.1103 C C C C T T A A A A A A G G
fluidigm.759 -2.1103 C C T T T T A G A A A A G G
fluidigm.760 5.9687 C C C T T T A A A A A G G G
fluidigm.761 6.8897 C C C C T T A G A G A G G G
fluidigm.762 -6.9153 C C C C T T A G A A A G G G
fluidigm.763 0.8897 C C C T T T A G A G A G G G
fluidigm.764 4.1885 C T C C T T A A A G A A G G
fluidigm.765 -2.3841 C T T T T T A G G G A A G G
fluidigm.766 -4.6384 C C C C T T A G A A A A G G
fluidigm.767 5.2804 C C C T T T A A G G A A G G
fluidigm.768 11.3177 C C C T C T A G G G A A G G
fluidigm.769 4.2420 C C T T T T A A G G A A G G
fluidigm.770 5.0958 C C C T T T A A A A A A C G
fluidigm.771 -21.7580 C C T T T T A G G G A A C G
fluidigm.772 -13.1103 C C C T T T A A A A A A G G
fluidigm.773 -4.7196 C C C C T T A G A A A A C G
fluidigm.774 0.8897 C C C C T T A A A A A A G G
fluidigm.775 -1.8443 C C C T T T A A G G A A G G
fluidigm.776 -12.9042 C C T T C T A A A A A A G G
fluidigm.777 4.3177 C C C T T T A A A G A A C G
fluidigm.778 4.1885 C C C T T T A A A G A G G G
fluidigm.779 12.3177 C C T T T T A A A G A A G G
fluidigm.780 -1.7196 C C C T T T G G A A A G G G
fluidigm.781 13.1557 C C T T T T A A A G A A G G
fluidigm.782 -7.9153 C C C T T T G G G G A A G G
fluidigm.783 -3.9042 C T T T C T A A A A A A G G
fluidigm.784 -2.1103 C C T T T T A A A A A A G G
fluidigm.785 -6.0313 C C C C T T A A G G A A G G
fluidigm.786 12.1557 C C T T T T A A A G A A G G
fluidigm.787 -8.3841 C C T T T T G G A G A G G G
fluidigm.788 -4.6823 C T C T C T A A A G A A G G
fluidigm.789 -3.5680 C C T T T T A A A G A A G G
fluidigm.790 0.8897 C C C C T T A G A G A A C G
fluidigm.791 0.4320 C C T T T T A G G G A A C G
fluidigm.792 -10.1103 C C C T T T A A 0 0 A A C G
fluidigm.793 -2.6384 C C T T T T A A A A A A G G
fluidigm.794 9.2420 C C C T T T A A G G A A G G
fluidigm.795 -3.5680 C C T T T T A A G G A A G G
fluidigm.796 13.2804 C C T T T T A A A G A A G G
fluidigm.797 4.3616 C C T T T T A G G G A A 0 0
fluidigm.798 4.4671 C C T T T T A A G G A A G G
fluidigm.799 -3.6384 C C T T T T A G G G A A G G
fluidigm.800 0.3177 C C C T T T A G G G A A G G
fluidigm.801 5.0958 C C C T T T A A G G A A G G
fluidigm.802 -1.6384 C T C T T T A A A G A A G G
fluidigm.803 11.8897 C C C T T T A G A G A A G G
fluidigm.804 -3.1103 C C C T T T A G G G A A G G
fluidigm.805 19.0958 C C T T T T A G G G A G G G
fluidigm.806 8.8897 C C T T T T A A A G A A G G
fluidigm.807 5.2420 C C C C T T A A G G A G G G
fluidigm.808 9.0958 C C C T T T A A G G A A G G
fluidigm.809 1.3616 C C T T T T A A G G A A G G
fluidigm.810 3.1557 C C C T T T A A A A A A G G
fluidigm.811 3.4671 C C T T T T A G A G A A G G
fluidigm.812 -2.1655 C C C C T T A G A A A A G G
fluidigm.813 11.2804 C C C T T T A G G G A A G G
fluidigm.814 -2.6823 C T C T T T A A A G A G G G
fluidigm.815 5.2420 C C T T T T A G A A A A G G
fluidigm.816 -5.7580 C C T T T T A A A G A A G G
fluidigm.817 -1.9042 C C C C T T A A A G A G G G
fluidigm.818 13.0847 C C C C T T A G A G A G G G
fluidigm.819 14.3177 C C C T T T A A A A A A G G
fluidigm.820 -10.9042 C C C C T T A A A A A A G G
fluidigm.821 11.3177 C C C C T T A A A G A A C G
fluidigm.822 1.9687 C C C T T T A G A G A G G G
fluidigm.823 -0.1103 C C C T C T A A G G A A G G
fluidigm.824 1.2420 C C C T T T A A A G A A G G
fluidigm.825 -0.6384 C T C T T T A G G G A A G G
fluidigm.826 -1.3841 C C C C T T A A A A A A G G
fluidigm.827 -1.7580 C T C T T T A G G G A A G G
fluidigm.828 -7.1103 C C C C T T A A A G A A C G
fluidigm.829 1.1885 C C T T T T A A A A A A G G
fluidigm.830 7.2804 C C T T T T A A G G A A G G
fluidigm.831 1.2420 C C T T T T A G G G A G G G
fluidigm.832 3.4320 C C T T T T A G A A A G G G
fluidigm.833 6.3177 C C C C T T A A A A A A G G
fluidigm.834 -0.7580 C C T T T T A A A A A G G G
fluidigm.835 0.0958 C C C T T T A G A A A A G G
fluidigm.836 -13.7580 C C T T T T A A G G A A G G
fluidigm.837 -2.6384 C C C T T T A A G G A G G G
fluidigm.838 9.2804 C C T T T T A A G G A G C G
fluidigm.839 -2.5680 C C T T T T A A G G A A C G
fluidigm.840 -0.6823 C C T T T T A G G G A A C G
fluidigm.841 3.4671 C C T T T T A A G G A A C G
fluidigm.842 0.0847 C C C T T T G G G G 0 0 G G
fluidigm.843 -3.7580 C C C T T T A A A G A A G G
fluidigm.844 2.0958 C C C C T T A A A G A A G G
fluidigm.845 -26.6823 C C T T T T A A G G A A G G
fluidigm.846 -0.9153 C C C C T T A A A G A A G G
fluidigm.847 8.4320 C C T T T T A A G G A A G G
fluidigm.848 10.3177 C C T T T T A A A G A A G G
fluidigm.849 -12.6823 C C T T T T A A G G A A G G
fluidigm.850 -2.7196 C C C T T T A A A G A A G G
fluidigm.851 -4.7196 C C T T T T A A A G A A G G
fluidigm.852 8.8897 C C C T T T A A A A A A G G
fluidigm.853 6.1885 C C C T T T A A G G A A G G
fluidigm.854 -2.7580 C C T T T T A A G G A A G G
fluidigm.855 -8.7196 C C C T T T A A G G A A G G
fluidigm.856 7.6159 C C C C T T A A A G A A G G
fluidigm.857 1.8897 C C C C T T A G G G A A G G
fluidigm.858 11.0958 C C C T T T A A A A A A G G
fluidigm.859 -0.3841 C C C T T T A A A G A A G G
fluidigm.860 -4.1103 C C C C T T A G A A A A C G
fluidigm.861 -2.5680 C C T T T T A G G G A A G G
fluidigm.862 -6.1103 C C T T T T A A A G A A G G
fluidigm.863 0.8897 C C T T T T A A G G A A G G
fluidigm.864 4.0958 C C C T T T A G A G A A G G
fluidigm.865 0.3177 C C T T T T A G A G A A G G
fluidigm.866 -7.3841 C C C C T T A A G G A A G G
fluidigm.867 -0.5680 C C C C T T A G G G A A G G
fluidigm.868 -3.6384 C C C T T T A A A G A A C G
fluidigm.869 -0.7580 C C C T C T A G G G A G G G
fluidigm.870 3.2420 C C C T T T A G G G A A G G
fluidigm.871 -9.5680 C C T T T T A G G G A A C G
fluidigm.872 10.3177 C C T T T T A G G G A G G G
fluidigm.873 0.4320 C C C T T T A A G G A A G G
fluidigm.874 10.2420 C C C T T T A G G G A A G G
fluidigm.875 3.2420 C C T T T T A A G G A A G G
fluidigm.876 -0.0313 C C C T T T A A A A 0 0 G G
fluidigm.877 5.9847 C C T T T T A A A G A A G G
fluidigm.878 6.3177 C C C C C T A A A A A A G G
fluidigm.879 0.3177 C C C T T T A A A G A A G G
fluidigm.880 11.2804 C T C T T T A A G G A A G G
fluidigm.881 0.2420 C C C T T T A G A G A A G G
fluidigm.882 1.3616 C C T T T T A A A G A A G G
fluidigm.883 -3.3841 C C C T T T A A G G A G G G
fluidigm.884 10.0847 C T T T T T A G A A A A G G
fluidigm.885 -1.6823 C C C T T T A A A A A A G G
fluidigm.886 -9.5680 C T C T T T A A G G A A G G
fluidigm.887 11.6159 C C C T T T A A G G A G G G
fluidigm.888 -8.6823 C C T T T T A A G G A A G G
fluidigm.889 13.0781 C C C T T T A A A G A G C G
fluidigm.890 -14.1103 C C C T T T A A A A A A G G
fluidigm.891 -4.1103 C C C T T T A G A G A G G G
fluidigm.892 6.9847 C C T T T T A A A G A A G G
fluidigm.893 1.8897 C C C T C T A A G G 0 0 G G
fluidigm.894 2.2420 C C C T T T A G A G A A G G
fluidigm.895 8.3177 C C C T T T A G G G A G G G
fluidigm.896 -0.9042 C C T T C T A A A G A A G G
fluidigm.897 6.2804 C C C C T T A A A G A A G G
fluidigm.898 8.3616 C C T T T T A A A G A A G G
fluidigm.899 -1.8115 C T C T T T A A A G A A G G
fluidigm.900 -25.9042 C C T T C T A G G G A A G G
fluidigm.901 -4.9153 C C C T T T A A G G A A G G
fluidigm.902 4.1557 C C T T T T A A A G A A G G
fluidigm.903 -3.6823 C C C T T T A A G G A G G G
fluidigm.904 -5.6823 C C C C T T A A A G A A G G
fluidigm.905 -3.9042 T T C T T T A A A G A A G G
fluidigm.906 11.8897 C C T T T T A G A G A A C G
fluidigm.907 8.3177 C C C T T T A A A A A G G G
fluidigm.908 1.0847 C C T T T T A A G G A A G G
fluidigm.909 8.3177 C T T T T T A G A G A G G G
fluidigm.910 7.3616 C C C C T T A A G G A A G G
fluidigm.911 2.2420 C C C C T T A A A G A A G G
fluidigm.912 -7.5680 C T T T T T A G A A A A G G
fluidigm.913 -2.6823 C C T T T T A G A G A A G G
fluidigm.914 -5.5680 C C C T T T A G G G A A G G
fluidigm.915 -6.5680 C C C T T T A A G G A A G G
fluidigm.916 -1.9153 C C T T T T A A G G A A G G
fluidigm.917 7.3177 C C C C T T A G A G A A G G
fluidigm.918 1.2420 C C C T T T A A A A A A G G
fluidigm.919 13.2420 C C C C T T A G G G A A G G
fluidigm.920 0.0958 C C T T T T A A G G A A G G
fluidigm.921 13.2420 C C T T C T A A A A A A G G
fluidigm.922 -7.7580 C C T T T T A A A A A G G G
fluidigm.923 -7.7580 C C T T T T A G A G A G G G
fluidigm.924 -5.7196 C C C T T T G G G G A A G G
fluidigm.925 -7.9153 C C T T T T G G G G A A G G
fluidigm.926 0.3177 C C T T T T A A A G A A G G
fluidigm.927 3.8897 C C T T T T A A A G A G G G
fluidigm.928 -12.6823 C C C T T T A G G G A A G G
fluidigm.929 1.2420 C C C T T T A A A A A A G G
fluidigm.930 -6.9042 C C C T T T A A A G A A G G
fluidigm.931 -4.6384 T T C C T T A A G G A A G G
fluidigm.932 7.2420 C C T T T T A G A G A G G G
fluidigm.933 0.4320 C C T T T T A A A G A A G G
fluidigm.934 3.4671 C C C T C T A A G G A A G G
fluidigm.935 4.2804 C C C T T T A A A A A A G G
fluidigm.936 2.4320 C T C T T T A A G G A A G G
fluidigm.937 1.0847 C C C T T T A A G G A A G G
fluidigm.938 -1.1103 C C T T C T G G A G A A G G
fluidigm.939 9.2420 C C C T T T A A A G A A G G
fluidigm.940 2.8897 C C C C T T A A G G A A G G
fluidigm.941 10.2420 C C C T T T A G G G A A G G
fluidigm.942 12.2420 C C C T T T A A A A A A G G
fluidigm.943 4.2420 C C C T T T A G G G A A G G
fluidigm.944 -1.9042 C C T T T T A A A G A A G G
fluidigm.945 3.8897 C C C T T T A A A A A A G G
fluidigm.946 10.9687 C C T T T T A A G G A A G G
fluidigm.947 0.8897 C C C C T T A A G G A A G G
fluidigm.948 6.2420 C C C T T T A A A G A A G G
fluidigm.949 -0.1103 C C C T T T A A A G A G G G
fluidigm.950 -14.1103 C C T T T T G G A G A A G G
fluidigm.951 6.0781 C C T T T T A A G G G G G G
fluidigm.952 13.0958 C C T T T T A A G G A A G G
fluidigm.953 5.3177 C C T T T T A A A G A A G G
fluidigm.954 17.3177 C C C C T T A G A G A A G G
fluidigm.955 13.8897 C C 0 0 T T A A A G A A G G
fluidigm.956 1.4320 C C C T T T A A A A A A G G
fluidigm.957 -2.8443 C C C T T T A A A G A G G G
fluidigm.958 -8.7580 C C C T T T A A A A A A G G
fluidigm.959 -1.7580 C C T T T T A A A G A A G G
fluidigm.960 -2.6823 C C C T T T A A G G A A G G
fluidigm.961 -3.6384 T T C C T T A A A A A A G G
fluidigm.962 -4.7580 C C C C T T 0 0 A G A A G G
fluidigm.963 -0.7580 C C T T T T A A A G A A G G
fluidigm.964 -0.7580 C T 0 0 C T G G A G A G G G
fluidigm.965 -7.7196 C T C T T T 0 0 A G A A G G
fluidigm.966 -1.3841 C C C T T T A G A A A G G G
fluidigm.967 10.2420 C C C C T T A A G G A A G G
fluidigm.968 12.8897 C C T T T T A A A G G G G G
fluidigm.969 -0.6384 C C C C T T A G A G A A G G
fluidigm.970 3.0958 C C T T T T A G G G A A G G
fluidigm.971 4.0847 C C C T T T 0 0 G G A A G G
fluidigm.972 -1.5680 C C 0 0 T T A A A G A G G G
fluidigm.973 3.2804 C C C T T T A G A G A G G G
fluidigm.974 1.0958 C T C T T T A A G G A G G G
fluidigm.975 -3.6823 C C T T T T A G A A A A G G
fluidigm.976 8.8897 C C C T T T A A A A A A G G
fluidigm.977 -6.7580 C T T T T T 0 0 G G A G G G
fluidigm.978 10.0781 C C C T T T A A G G A G G G
fluidigm.979 -1.6823 C C T T C T G G A G A A G G
fluidigm.980 -4.5680 C C T T T T A G A G A A C G
fluidigm.981 -4.6384 C C T T T T A G G G A A C G
fluidigm.982 -5.7196 C C C T T T G G G G A G G G
fluidigm.983 0.8897 C C T T T T A A G G A A G G
fluidigm.984 1.8897 C C 0 0 T T A A G G A A G G
fluidigm.985 0.8897 C C C T T T A G G G A A G G
fluidigm.986 -13.7580 C C C C T T A A G G A A G G
fluidigm.987 12.3177 C C C T T T A G A A A A G G
fluidigm.988 -8.3841 C T 0 0 T T A A A G A A C G
fluidigm.989 -6.5680 C C C C T T A A A A 0 0 G G
fluidigm.990 -1.6384 C C T T C T A A G G 0 0 G G
fluidigm.991 11.0958 C C C T T T 0 0 A G A A G G
fluidigm.992 2.8897 C C 0 0 T T A A G G A A G G
fluidigm.993 3.9847 C C T T C T A G A G A A G G
fluidigm.994 -12.6823 C C C C T T A A G G A A G G
fluidigm.995 -1.5680 C C T T T T A G A G A A G G
fluidigm.996 -5.7580 C C C T T T A G A G A A G G
fluidigm.997 -2.6823 C C 0 0 T T A G G G A G G G
fluidigm.998 -12.9042 C C C T T T A A A G A A 0 0
fluidigm.999 -6.9042 C C T T T T A G A G A A G G
fluidigm.1000 -2.3841 C C C C T T A A A A A A G G
fluidigm.1001 14.3616 C C C C C T A G A G A A G G
fluidigm.1002 3.1557 C C C C T T A G A G A A G G
fluidigm.1003 4.2420 C C C T T T A A A G A A G G
fluidigm.1004 6.0958 C C C T T T A G A G A A G G
fluidigm.1005 0.2804 C C C T T T A A G G A A G G
fluidigm.1006 -5.1103 C C 0 0 T T A A A G A A G G
fluidigm.1007 6.0958 C C T T T T A G A G A G G G
fluidigm.1008 -1.7580 C C C T T T A G A G A A G G
fluidigm.1009 0.8897 C C C T T T A A G G A G G G
fluidigm.1010 0.1557 C C T T T T A A A G A A G G
fluidigm.1011 4.0847 C C T T T T G G G G A G G G
fluidigm.1012 10.2420 C C C T T T A G A G A A G G
fluidigm.1013 4.0847 C C 0 0 T T A G A G A G G G
fluidigm.1014 0.8897 C C C T T T A A A A A A G G
fluidigm.1015 -0.1103 C C C T T T A A G G A G C G
fluidigm.1016 -15.9042 C C C T T T A G G G A G G G
fluidigm.1017 14.4320 C C C T T T G G A G A A G G
fluidigm.1018 -5.5680 C C C C T T A A A G A G G G
fluidigm.1019 -6.7196 C C C C T T A A A G A A G G
fluidigm.1020 -3.7196 C C T T T T A A A A A A G G
fluidigm.1021 12.0847 C C C T T T A A G G 0 0 G G
fluidigm.1022 14.2804 C C C C T T A A A G A A G G
fluidigm.1023 3.8897 C C C T T T A A A A A A G G
fluidigm.1024 -4.7196 C C C T T T A G G G A G G G
fluidigm.1025 7.3177 C C C T T T A G A G A A G G
fluidigm.1026 -13.7196 C C T T T T A G A A A G G G
fluidigm.1027 0.8897 C C T T T T A A A A A A G G
fluidigm.1028 10.9687 C C C C T T A A A G A A G G
fluidigm.1029 2.0958 C C C T T T A G A G A A G G
fluidigm.1030 1.2804 C C C C T T A G G G A G G G
fluidigm.1031 -14.6823 C C C T C T A G G G A A G G
fluidigm.1032 2.2804 C C C C T T A G G G A A G G
fluidigm.1033 -10.7196 C C C T T T A G A A A A G G
fluidigm.1034 -10.7580 C C C C T T A A A G A A G G
fluidigm.1035 6.3616 C C C T T T A G G G A A G G
fluidigm.1036 -0.6384 C C C T T T A A G G A A G G
fluidigm.1037 3.2420 C C C T T T A G A G A G G G
fluidigm.1038 -15.9042 C C C T T T A G A G A A G G
fluidigm.1039 2.1885 C C C T T T A A G G A A G G
fluidigm.1040 1.3616 C C T T T T A A A A A A G G
fluidigm.1041 -2.1103 C C T T T T A A A G A A G G
fluidigm.1042 5.4320 C C T T T T A A A G A A G G
fluidigm.1043 12.4671 C C T T T T A A A G A A G G
fluidigm.1044 -3.7196 C C C T T T A A G G A A C G
fluidigm.1045 2.0958 C C T T T T A A A G A A G G
fluidigm.1046 -2.0313 C C C T T T A A A G A A G G
fluidigm.1047 19.3177 C C C T T T A A G G A A G G
fluidigm.1048 -7.7196 C C T T T T A A A G A A G G
fluidigm.1049 -0.9153 C C C T T T A A A G A A G G
fluidigm.1050 -10.7196 C C C T C T A G A A A G G G
fluidigm.1051 6.9687 C C T T T T A G A G A G G G
fluidigm.1052 -10.6823 C C C T T T A G A G A A G G
fluidigm.1053 -6.6384 C C C C T T A A G G A A G G
fluidigm.1054 9.2420 C C C T T T A A G G A G G G
fluidigm.1055 4.3177 C C C T T T A G A G A A C G
fluidigm.1056 0.2804 C C C T T T A A G G A G G G
fluidigm.1057 -6.6384 C C T T T T A A G G A A G G
fluidigm.1058 21.0958 C C T T T T A A A G A A G G
fluidigm.1059 -9.1103 C C T T T T A A A G A A G G
fluidigm.1060 -0.9153 C C T T T T A A G G A G G G
fluidigm.1061 -6.5680 C C T T T T A G A G A A G G
fluidigm.1062 -1.6384 C C C T T T A G A G A A G G
fluidigm.1063 8.8345 C C C C T T A A A G A A G G
fluidigm.1064 1.3177 C T C T T T A G G G A A G G
fluidigm.1065 -1.9153 C C C C T T A A A G A A G G
fluidigm.1066 0.3177 C C C T T T A A G G A G G G
fluidigm.1067 -4.5680 C C C T T T A A A G A A C G
fluidigm.1068 -5.6823 C T T T C T A A G G A A G G
fluidigm.1069 -1.7580 C C T T T T A A A G A A G G
fluidigm.1070 -8.7580 C T C T C T A A A A A A G G
fluidigm.1071 5.2420 C C C T T T A A A G A A G G
fluidigm.1072 -2.1103 C C T T T T A A G G A A G G
Table S2. SNPs analyzed in replication samples and for polygenic modification score.
From Fluidigm genotype data, 61 independent SNPs were chosen to be analyzed for polygenic modification score. S
Use of the Fluidigm platform for replication analysis required us to choose 96 SNPs as a single genotyping panel, an
MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium
SNP Chromosome BP (hg19) Minor alleleMajor allele
Discovery set (GWA)
MAF Effect size / minor alleleP-value
rs113605276 1 8,623,490 T C 0.046 -0.83 3.90E-02
rs1146382 1 85,918,101 C T 0.417 0.65 8.11E-05
rs115068682 1 108,450,969 C T 0.035 -2.02 4.49E-06
rs45576236 1 112,319,388 G A 0.194 0.71 1.03E-03
rs3820400 1 168,074,746 A G 0.388 0.78 1.19E-05
rs10159075 1 204,160,370 G A 0.091 -0.89 1.88E-03
rs75376497 1 248,086,661 C G 0.035 -2.05 3.44E-06
rs144741933 2 11,230,267 A C 0.017 -2.86 4.44E-06
rs4854546 2 69,317,925 G A 0.109 -0.93 5.22E-04
rs72810940 2 75,555,265 A G 0.029 2.43 5.88E-07
rs6751149 2 127,924,981 C T 0.476 0.65 2.20E-05
rs778194 2 137,599,040 C A 0.469 0.59 4.97E-04
rs13017290 2 202,909,097 C T 0.477 0.69 3.93E-05
rs17036872 3 12,559,188 A G 0.167 -0.90 2.54E-05
rs17197692 3 36,775,946 C A 0.059 -1.38 6.33E-05
rs1799977 3 37,053,568 G A 0.319 0.90 7.16E-07
rs34625289 3 64,696,009 A G 0.111 -0.97 1.92E-04
rs1491738 3 68,276,485 T C 0.286 0.69 7.87E-05
rs2289596 3 111,701,173 C T 0.207 0.57 1.13E-02
rs7652523 3 171,674,996 C G 0.389 0.60 7.29E-04
rs7627373 3 190,763,662 A G 0.168 -0.89 1.03E-04
rs890490 3 196,750,207 A G 0.197 0.81 4.22E-05
rs77304846 4 70,495,353 C T 0.182 -0.74 6.14E-04
rs143869898 4 105,077,431 A G 0.015 -3.05 1.72E-05
rs10005354 4 167,869,220 G T 0.098 1.07 7.70E-05
rs72713682 4 178,684,282 C T 0.018 -2.61 1.53E-05
rs12655177 5 2,156,456 T C 0.108 1.10 1.48E-05
rs7704337 5 113,670,134 G A 0.266 0.80 2.58E-05
rs79274321 5 121,660,713 A G 0.058 -1.42 3.70E-05
rs67972044 5 155,987,761 C G 0.052 -1.67 4.91E-06
rs13157017 5 156,610,285 C T 0.028 -2.12 2.31E-05
rs115775808 5 159,350,164 T C 0.023 -2.45 5.59E-06
rs9466071 6 21,392,004 A G 0.364 0.65 1.49E-04
rs6934819 6 132,095,805 A C 0.069 -1.49 2.81E-06
rs1247336 6 161,377,557 C T 0.245 -0.86 2.14E-05
rs917810 7 21,061,360 G C 0.383 0.74 3.17E-05
rs701280 7 83,533,062 T C 0.446 -0.44 6.58E-03
rs79959239 7 131,887,315 T C 0.011 3.18 2.98E-05
rs116940312 8 9,230,961 G C 0.035 1.92 7.14E-05
rs9325798 8 16,644,586 C T 0.021 2.41 1.54E-05
rs16896685 8 99,155,532 A G 0.125 -1.04 2.99E-05
rs34852161 8 103,284,508 A C 0.083 -1.48 3.43E-07
rs7837873 8 125,225,255 A G 0.397 0.74 3.54E-05
rs148414929 9 92,077,451 A G 0.028 -1.74 2.72E-04
rs12412337 10 113,652,642 A G 0.049 1.53 8.60E-05
rs148942750 11 43,738,055 C T 0.014 -3.12 6.33E-06
rs150429450 11 58,854,570 G A 0.023 2.21 5.77E-05
rs481871 11 79,354,702 A G 0.095 -1.21 8.21E-06
rs10892160 11 117,552,640 G A 0.194 -0.80 9.95E-05
rs11062045 12 2,098,435 T A 0.144 1.01 1.42E-05
rs150393409 15 31,202,961 A G 0.016 -5.55 0.00E-16
rs35811129 15 31,241,346 A G 0.272 1.38 1.16E-13
rs61064919 16 13,343,332 T G 0.190 -0.88 2.05E-05
rs16975803 16 23,051,026 T C 0.363 0.68 6.24E-05
rs1486437 16 51,899,860 G A 0.116 -1.19 2.03E-06
rs74611520 16 56,981,126 T G 0.112 1.08 4.51E-05
rs72863909 18 1,700,716 G C 0.102 -1.07 1.13E-04
rs80324765 18 43,344,674 A G 0.077 -0.99 2.61E-03
rs6136301 20 18,108,215 T A 0.055 -1.50 2.07E-05
rs62215296 20 24,564,646 A G 0.278 0.59 2.31E-03
rs738972 22 33,986,668 C T 0.205 -0.76 1.29E-04
ingle SNP association analysis results in the Fluidigm data are shown.
d therefore we selected SNPs based on relatively relaxed criteria that considered nominal association significance in e
Replication set (Fluidigm) Meta-analysis
Nearest gene(s)Call rate (%) HWE p-value MAF Effect size / minor alleleP-value P-value
100.0 1.2E-01 0.046 0.09 8.27E-01 1.65E-01RERE
97.2 6.9E-01 0.413 -0.11 5.51E-01 1.08E-02DDAH1
99.7 3.9E-01 0.043 0.02 9.69E-01 7.14E-04VAV3
98.3 2.3E-01 0.178 -0.25 2.93E-01 8.06E-02KCND3
99.4 2.9E-01 0.387 0.00 9.84E-01 1.07E-03GPR161
93.0 2.3E-01 0.090 0.03 9.32E-01 2.20E-02KISS1
99.2 5.8E-01 0.033 -0.39 4.47E-01 7.40E-05OR2T8
99.9 3.1E-01 0.011 -0.02 9.79E-01 6.08E-04FLJ33534
95.7 4.3E-01 0.114 0.68 2.11E-02 2.81E-01ANTXR1
99.9 6.4E-01 0.020 -0.33 6.17E-01 7.32E-04TACR1
99.4 6.2E-01 0.476 0.44 1.62E-02 1.90E-06CYP27C1
97.6 2.6E-01 0.479 -0.04 8.41E-01 1.36E-02THSD7B
99.8 3.3E-01 0.469 -0.11 5.49E-01 7.93E-03FZD7
99.5 7.0E-02 0.153 0.02 9.23E-01 2.16E-03TSEN2
99.5 3.7E-01 0.063 0.16 6.66E-01 7.22E-03DCLK3
99.7 6.8E-01 0.305 0.59 2.58E-03 1.19E-08MLH1
99.5 3.9E-01 0.115 0.17 5.61E-01 1.71E-02ADAMTS9-AS2
98.0 6.1E-01 0.296 0.01 9.56E-01 2.86E-03FAM19A1
97.9 3.6E-02 0.198 0.33 1.39E-01 4.03E-03ABHD10
95.7 9.8E-02 0.381 -0.10 5.99E-01 2.88E-02TMEM212-AS1
98.3 9.5E-01 0.179 0.00 9.96E-01 3.82E-03OSTN
99.3 6.2E-01 0.196 0.03 8.99E-01 1.74E-03MELTF
98.3 6.2E-01 0.171 -0.05 8.50E-01 7.35E-03UGT2A1 / UGT2A2
99.6 1.2E-01 0.006 1.13 3.19E-01 1.14E-02CXXC4
97.7 1.4E-02 0.086 0.06 8.60E-01 2.15E-03SPOCK3
99.5 2.3E-02 0.018 0.03 9.61E-01 1.46E-03LINC01098
99.6 2.7E-01 0.105 0.07 8.06E-01 7.13E-04LOC100506858
100.0 2.5E-01 0.267 -0.12 5.52E-01 6.37E-03KCNN2
94.7 3.9E-01 0.067 0.52 1.64E-01 2.90E-02SNCAIP
99.4 2.6E-01 0.049 -0.03 9.52E-01 5.85E-04SGCD
99.4 1.6E-01 0.025 0.07 8.99E-01 2.19E-03ITK
99.2 3.7E-01 0.020 0.88 1.77E-01 1.32E-02ADRA1B
98.4 5.8E-02 0.361 -0.17 3.53E-01 2.72E-02LINC00581
98.5 2.3E-01 0.062 -0.03 9.37E-01 3.94E-04ENPP3
97.3 4.7E-01 0.244 -0.18 3.94E-01 1.82E-04MAP3K4
98.9 1.7E-01 0.382 0.20 2.85E-01 1.37E-04LINC01162
94.9 8.9E-01 0.452 0.11 5.60E-01 9.74E-02SEMA3A
98.3 1.0E+00 0.010 0.32 7.28E-01 8.22E-04PLXNA4
99.9 2.9E-01 0.027 -0.43 4.46E-01 1.46E-02LOC157273
93.1 2.9E-01 0.027 0.82 1.54E-01 2.70E-05FGF20
98.7 6.3E-01 0.126 -0.08 7.71E-01 9.53E-04POP1
100.0 3.6E-01 0.084 -0.87 7.37E-03 2.39E-08UBR5
97.5 2.8E-02 0.400 -0.10 5.79E-01 6.51E-03LOC101927588
94.3 1.3E-01 0.020 -0.41 5.33E-01 1.63E-03SEMA4D
99.6 8.5E-01 0.048 0.05 9.00E-01 2.67E-03GPAM
99.9 1.0E+00 0.014 0.44 5.80E-01 2.84E-03HSD17B12
99.2 7.7E-01 0.030 -0.54 3.15E-01 2.02E-02FAM111B
99.4 1.9E-01 0.096 0.04 9.02E-01 1.21E-03TENM4
99.0 1.7E-01 0.196 -0.22 3.33E-01 3.94E-04DSCAML1
96.4 7.6E-02 0.146 0.12 6.45E-01 3.77E-04DCP1B
99.0 4.2E-01 0.013 -2.38 3.07E-03 0.00E-16FAN1
99.2 1.4E-01 0.265 1.30 2.09E-10 0.00E-16MTMR10
98.2 4.6E-01 0.193 0.49 3.23E-02 7.97E-02SHISA9
94.7 2.5E-01 0.364 0.27 1.58E-01 8.11E-05USP31
98.9 4.0E-01 0.119 0.03 9.14E-01 5.28E-04LINC01571
99.6 4.9E-02 0.110 -0.41 1.54E-01 3.75E-02HERPUD1
99.6 4.1E-01 0.080 -0.05 8.84E-01 3.00E-03LINC00470
99.5 1.4E-02 0.082 0.10 7.69E-01 4.11E-02SLC14A1
95.5 5.9E-01 0.053 -0.22 5.99E-01 3.97E-04PET117
96.4 4.8E-01 0.277 -0.14 5.00E-01 6.64E-02SYNDIG1
98.3 4.7E-02 0.206 -0.33 1.56E-01 1.44E-04LARGE1
ither the original standard continuous analysis or extreme dichotomous analysis of the discovery data set. Thus, many

 SNPs did not generate strong association signals in the replication data set.


